Original Article

You have full text access to this OnlineOpen article

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer

Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses

  1. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group†,‡,§,¶,‖,††,‡‡,*

Article first published online: 29 SEP 2003

DOI: 10.1002/cncr.11745

Issue

Cancer

Cancer

Volume 98, Issue 9, pages 1802–1810, 1 November 2003

Additional Information

How to Cite

The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group (2003), Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Cancer, 98: 1802–1810. doi: 10.1002/cncr.11745

Author Information

  1. †

    The following individuals are members of the ATAC Trial Steering Committee (asterisks denote members of the writing group for the current article): *Professor M. Baum (founding chairman and principal investigator for the main ATAC trial), University College London, London, United Kingdom; Professor A.R. Bianco, Universita degli Studi di Napoli Federico II, Naples, Italy; *Dr. A. Buzdar (vice chairperson elect for the main ATAC trial), The University of Texas M.D. Anderson Cancer Center, Houston, Texas; Dr. M. Coibion, Institut Bordet, Brussels, Belgium; Professor R Coleman, Cancer Research Centre, Weston Park Hospital, Sheffield, United Kingdom; Dr. M. Constenla, Hospital Montecelo, Pontevedra, Spain; *Professor J. Cuzick (independent statistician), Cancer Research UK, London, United Kingdom; Professor Dr. W. Distler, Carl Gustav Carus Universitætsklinkan Dresden, Dresden, Germany; Professor M. Dowsett, The Royal Marsden Hospital, London, United Kingdom; *Professor J. Forbes, Newcastle Mater Misericordiae Hospital, Newcastle, Australia; Professor W.D. George, Beatson Oncology Centre, Western Infirmary, Glasgow, United Kingdom; Sr. J. Gray, Belfast City Hospital, Belfast, United Kingdom; Dr. J.P. Guastalla, Centre Leon Berard, Lyon, France; *Mrs. J. Houghton and Dr. N. Williams, Clinical Trials Group of the Department of Surgery, University College London, London, United Kingdom; *Professor A. Howell (current chairman for the main ATAC trial), Christie Hospital, Manchester, United Kingdom; Professor Dr. J.G.M. Klijn, Dr. Daniel den Hoed Kliniek, Rotterdam, The Netherlands, and University Hospital Rotterdam, Rotterdam, The Netherlands; Dr. G.Y. Locker, Evanston Hospital, Kellogg Cancer Care Center, Evanston Illinois; Dr. J. Mackey, Cross Cancer Institute, Edmonton, Alberta, Canada; Professor R.E. Mansel, University of Wales College of Medicine, Cardiff, United Kingdom; Professor J.M. Nabholtz, University of California–Los Angeles, Los Angeles, California; Dr. T. Nagykalnai, Uzsoki University Hospital, Budapest, Hungary; Dr. A. Nicolucci, GIVIO Co-ordinating Centre, Consorzio Mario Negri Sud, Centro Di Ricerche Farmacologiche e Biomediche, Chieti, Italy; Dr. U. Nylen, Radiumhemmet, Karolinska Sjukhuset, Stockholm, Sweden; *Dr. T. Sahmoud and Dr. R. Hellmund, AstraZeneca Pharmaceuticals, Wilmington, Delaware; Mr. R. Sainsbury, University College London, London, United Kingdom; Dr. N. Griffiths and Dr. G. Hoctin-Boes, AstraZeneca Pharmaceuticals, Macclesfield, United Kingdom; Professor J.S. Tobias, The Meyerstein Institute of Clinical Oncology, Middlesex Hospital, London, United Kingdom.

  2. ‡

    The following individuals are members of the International Project Team: E. Foster, Scottish Cancer Therapy Network Central Office, Information and Statistics Division, Edinburgh, United Kingdom; N. Griffiths, A. Doe, and F. Sapunar, AstraZeneca Pharmaceuticals, Macclesfield, United Kingdom; J. Houghton and N. Williams, Clinical Trials Group of the Department of Surgery, University College London, London, United Kingdom; A. Nicolucci, Mario Negri Institute, Chieti, Italy; S. Pollard, Northern Yorkshire Clinical Trials Research Unit, Leeds, United Kingdom.

  3. §

    The following individuals are members of the Independent Data Monitoring Committee: Dr. M. Buyse, International Institute for Drug Development ID Squared, Brussels, Belgium; Dr. R. Margolese, McGill University, The Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada; Professor J.J. Body, Institute J. Bordet, Brussels, Belgium.

  4. The following individuals are members of collaborative/operational groups participating in ATAC: J.F. Forbes (group coordinator) and J.K. Wakeham (study coordinator), Australian New Zealand Breast Cancer Trials Group Operations Office, Ourimbah, Australia; S. de Placido (study coordinator) and C. Carlomagno (study coordinator), Universita degli Studi di Napoli Federico II, Naples, Italy; A. Nicolucci (group coordinator), M. Belfiglio (study coordinator), and M. Valentini (study coordinator), GIVIO Group, Consorzio Mario Negri Sud, Chieti, Italy; E. Foster (trial coordinator), Scottish Cancer Therapy Network, Information and Statistics Division, Edinburgh, United Kingdom; S. Pollard (trial coordinator), Northern & Yorkshire Clinical Trials Research Unit, University of Leeds, Leeds, United Kingdom; J. Houghton (senior lecturer in clinical trials) and N. Williams (trial coordinator), Clinical Trials Group of the Department of Surgery, University College London, London, United Kingdom.

  5. ‖

    Principal investigators and main coinvestigators in the ATAC trial: Argentina: Dr. F. Coppola and Dr. C. Bas, Hospital Aleman, Buenos Aires, Argentina; Dr. J. Itala and Dr. G. Cortese, Hospital de Clinicas, Buenos Aires University, Buenos Aires, Argentina; Dr. A. Nuñez de Pierro and Dr. D. Allemand, Hospital Gral de Agudos–Juan Fernandez, Buenos Aires, Argentina; Dr. R. Orti and Dr. R. Testa, Hospital Italiano, Buenos Aires, Argentina; Dr. J. Lebron, University of Buenos Aires, Buenos Aires, Argentina. Australia: Professor G. Gill and Dr. J. Kollias, Royal Adelaide Hospital, Adelaide, Australia; Dr. J. Chirgwin and Dr. M. Leyden, Box Hill Hospital, Box Hill, Australia; Dr. J. Beith and Dr. A. Sullivan, Royal Prince Albert Hospital, Camperdown, Australia; Dr. S. Della-Fiorentina and Dr. A. Goldrick, Liverpool Hospital, Liverpool, Australia; Dr. J. Chirgwin, Maroondah Hospital, Maroondah, Australia; Associate Professor G. Richardson and Dr. S. Hart, Monash Medical Centre, Melbourne, Australia; Associate Professor G. Toner and Dr. P. Francis, Peter MacCallum Cancer Institute, Melbourne, Australia; Dr. R. Snyder and Dr. I. Burns, St. Vincent's Hospital, Melbourne, Australia; Professor M. Friedlander and Dr. D. Goldstein, Prince of Wales Hospital, Randwick, Australia; Professor J. Forbes and Dr. D. Jackson, Newcastle Mater Misericordiae Hospital, Waratah, Australia. Belgium: Dr. A. Makar and Dr. D. Van den Weyngaert, AZ Middelheim, Antwerp, Belgium; Dr. D. Gangji and Dr. T. Velu, Hôpital Erasme, Brussels, Belgium; Dr. M. Coibion and Dr. J.-M. Nogaret, Institut Bordet, Brussels, Belgium; Dr. P. Neven and Dr. C. Laurent, St. Jan Ziekenhuis, Brussels, Belgium; Dr. J. De Mol and Dr. F. Van Aelst, Heilig Hart Ziekenhuis, Roeselare, Belgium. Canada: Dr. S.R. Sehdev, William Osler Health Centre, Brampton Memorial Hospital Campus, Brampton, Ontario, Canada; Dr. R. Simard, Complexe Hospitalier de la Sagami, Chicoutimi, Quebec, Canada; Dr. J.R. MacKey (former principal investigator, Dr. J.-M. Nabholtz), Cross Cancer Institute, Edmonton, Alberta, Canada; Dr. J. Dufresne, Centre Universitaire de Santé de l'Estrie (Fleurimont), Fleurimont, Quebec, Canada; Dr. W.S. Lofters, Kingston Regional Cancer Center, Kingston, Ontario, Canada; Dr. D.R. Holland, Lethbridge Cancer Clinic, Lethbridge, Alberta, Canada; Dr. H.L. Solow, Markham Stouville Health Centre, Markham, Ontario, Canada; Dr. J.A. Gapski, Trillium Health Centre, Mississauga, Ontario, Canada; Dr. S.H. Rubin (former principal investigator, Dr. O.R. Keller), South East Health Care Oncology Department, Moncton, New Brunswick, Canada; Dr. A. Robidoux, Centre Hospitalier de l'Université de Montréal–Campus Hotel-Dieu, Montreal, Quebec, Canada; Dr. B. Lesperance, Hospital Sacre Coeur, Montreal, Quebec, Canada; Dr. L.C. Panasci, Department of Oncology, McGill University, Montreal, Quebec, Canada; Dr. L.A. Zibdawi, York County Hospital, Newmarket, Ontario, Canada; Dr. J. Chang, Lakeridge Health, Oshawa, Ontario, Canada; Dr. M.L. Brigden (former principal investigator, Dr. D.L. Saltman), Penticton Regional Hospital, Penticton, British Columbia, Canada; Dr. R.F. Wierzbicki, Peterborough Regional Health Center Oncology Clinic, Peterborough, Ontario, Canada; Dr. B.P. Findlay, Department of Oncology, Hotel-Dieu Hospital, Quebec City, Quebec, Canada; Dr. J. Robert, CHA-Pavillion St. Sacrement, Quebec City, Quebec, Canada; Dr. S. Lebel (former principal investigator, Dr. M. Potvin), Hospital Laval, Quebec City, Quebec, Canada; Dr. M.R.B.T. Tirona, Allan Blair Cancer Center, Regina, Saskatchewan, Canada; Dr. M.J. Burnell, Atlantic Health Sciences Corporation, Saint John, New Brunswick, Canada; Dr. O.R. Keller (former principal investigator, Dr. B.A. Walley), Saskatoon Cancer Center, University of Saskatoon, Saskatoon, Saskatchewan, Canada; Dr. P.L.D. Walde, Group Health Centre, Sault Ste. Marie, Ontario, Canada; Dr. S.-C. Tang, H. Bliss Murphy Cancer Centre, St. John's, Newfoundland, Canada; Dr. C.J. Germond, Northeastern Ontario Regional Cancer Centre, Sudbury, Ontario, Canada; Dr. Y. Rahim, Toronto East General Hospital, Toronto, Ontario, Canada; Dr. J.J. Wilson, Humber River Regional Hospital, Weston, Ontario, Canada; Dr. A.L. Cooke (former principal investigator, Dr. D.M. Bowman), Manitoba Cancer Treatment and Research Foundation, Winnipeg, Manitoba, Canada. Czech Republic: Dr. K. Petrakova and Dr. R. Demlova, Masarykuv Onkologicky Ustav, Brno, Czech Republic; Dr. P. Vodvarka and Dr. T. Kysela, FNsP Ostrava, Ostrava-Poruba, Czech Republic; Dr. B. Konopasek and Dr. P. Mares, Vseobecna Fakultni Nemocnice, Prague, Czech Republic. France: Professor J.-Edouard Mention, Centre de Gyneco-Obstetrique, Centre Hospitalier Universitaire, Amiens, France; Dr. D. Serin and Dr. Y. Goubely-Brewer, Clinique Ste. Catherine, Avignon, France; Professor J.-P. Labat and Dr. J.-P. Malhaire, Centre Hospitalier Universitaire de Brest, Brest, France; Dr. G. Devulder and Dr. S. Mirdat-Dako, Centre Hospitalier Laënnec, Creil, France; Professor D. Houze De L'Aunoit and Dr. J.-Y. Charvolin, Hôpital St. Philibert, Lomme, France; Dr. J.-P. Guastalla and Dr. T. Bachelot, Centre Léon Bérard, Lyon, France; Dr. R. Coquard and Dr. B. Velay, Clinique St. Jean, Lyon, France; Dr. C. Lejeune and Dr. D. Hadjadj-Aoul, Hôpital de la Conception, Marseille, France; Dr. M. Untereiner and Dr. O. Rixe, Hôpital–Clinique Claude Bernard, Metz, France; Professor F. Laffargue, Hôpital Arnaud de Villeneuve, Montpellier, France; Dr. M. Rios, Centre Alexis Vautrin, Nancy, France; Dr. J.-M. Vannetzel and Dr. R. Mahjoubi, Centre Chirurgical Henri Hartmann, Neuilly sur Seine, France; Dr. R. Samak, Cabinet Medical, Nice, France; Dr. F. Morvan and Dr. F. Rousseau, Centre Hospitalier, Pontoise, France; Dr. C. Veyret and Dr. J.P. Julien, Centre Henri Becquerel, Rouen, France; Dr. B. Cutuli and Dr. P. Quetin, Centre Paul Strauss, Strasbourg, France; Professor J.-P. Brettes and Dr. C. Mathelin, Hôpital Civil, Strasbourg, France. Germany: Professor Dr. W. Distler and Dr. A. Schindelhauer, Universidtsklinik Carl Gustav Carus Dresden, Dresden, Germany; Professor Dr. W. Jaeger and Dr. G. Wieland, Frauenklinik Friedrich-Alexander–Universitæt Erlangen-Nuernberg, Erlangen, Germany; Dr. C. Oberhoff and Dr. D. Hanisch, Zentrum f. Frauenheilkunde Universitætsklinikum Essen, Essen, Germany; Dr. J. Bechler and Dr. S. Malur, Klinik f. Frauenheilkunde u. Geburtshilfe Friedrich-Schiller-Universitæt Jena, Jena, Germany; Professor Dr. W. Eiermann and Dr. G. Raab, Frauenklinik vom Roten Kreuz, Munich, Germany. Hungary: Dr. J. Fodor and Dr. C. Polgar, National Oncology Institute, Budapest, Hungary; Dr. K. Moskovits and Dr. Z. Nagy, St. Imre Hospital, Budapest, Hungary; Dr. T. Nagykalnai and Dr. L. Landherr, Uzsoki St. Hospital, Budapest, Hungary; Dr. T. Pinter and Dr. G. Herodek, Petz Aladar Hospital, Gyor, Hungary; Dr. B. Piko and Dr. I. Szegedi, Pandy Kalman County Hospital, Gyula, Hungary; Dr. J. Szanto and Dr. L. Marazi, BAZ County Hospital, Miskolc, Hungary; Dr. Z. Kahan, SZTE Oncotherapy Clinic, Szeged, Hungary. Ireland: Mr. E. McDermott and Professor N. O'Higgins, St. Vincent's Hospital, Dublin, Ireland; Professor T. Gorey, The Mater Hospital, Dublin, Ireland; Professor F. Given and Dr. S. Tormey, University College Galway, Galway, Ireland. Italy: Dr. M. Bonsignori and Dr. S. Rossini, Ospedale Torrette, Ancona, Italy; Dr. F. Di Vito and Dr. M. Cucchi, Ospedale Regionale, Aosta, Italy; Dr. F. Testore and Mrs. L. Giaretto, Ospedale Civile, Asti, Italy; Dr. F. Recchia and Dr. S. De Filippis, Ospedale Civile, Avezzano, Italy; M. De Lena and Dr. F Schittulli, Istituto Scientifico Oncologico, Bari, Italy; Dr. A. Martoni and Dr. E. Piana, Ospedale Sant'Orsola–M. Malpighi, Bologna, Italy; Dr. G. Marini and Dr. P. Marpicati, Spedali Civili, Brescia, Italy; Dr. M. Pintus and Dr. A. Tedde, Ospedale Oncologico A. Businco, Cagliari, Italy; Dr. M. Botta and Dr. D. Degiovanni, Ospedale Santo Spirito, Casale Monferrato, Italy; Dr. L. Basilico and Dr. M. Taraborrelli, Ospedale SS Annunziata, Chieti, Italy; Dr. S. Bravi and Dr. F. Biagioni, Ospedale Civile, Città di Castello, Italy; Dr. M. Giordano and Dr. G. Luchena, Ospedale Sant'Anna, Como, Italy; Dr. G. Scognamiglio and Dr. A. Beretta, Ospedale Valduce, Como, Italy; Professor P. Marchetti and Dr. M.E. D'Addario, Università degli Studi, Coppito, Italy; Dr. M. Obialero and Dr. F. Peradotto, Ospedale Civile, Cuorgné, Italy; Dr. M. Indelli and Dr. G. Lelli, Arcispedale Sant'Anna, Ferrara, Italy; Dr. A. Nuzzo and Dr. L. Laudadio, Ospedale Floraspe Renzetti, Lanciano, Italy; Dr. M. D'Aprile and Dr. M. Natali, Ospedale Santa Maria Goretti, Latina, Italy; Dr. G. Cruciani and Dr. E. Montanari, Ospedale Umberto I, Lugo, Italy; Dr. E. Aitini and Dr. G. Cavazzini, Ospedale C. Poma, Mantova, Italy; Professor V. Adamo and Professor G. Altavilla, Policlinico Universitario G. Martino, Messina, Italy; Dr. S. Barni and Dr. A. Ardizzoia, Ospedale San Gerardo, Monza, Italy; Dr. A. De Matteis and Dr. G. Landi, Istituto Nazionale Studi e Cura Tumori G. Pascale, Naples, Italy; Dr. G. D'Aiuto and Dr. R. Thomas, Istituto Nazionale Tumori G. Pascale, Naples, Italy; Dr. R. Lauria and Dr. M. De Laurentis, Universita Federico II, Naples, Italy; Dr. A. Fornasiero and Dr. H. Koussis, Ospedale Civile, Padua, Italy; Dr. G. Brignone and Dr. L. Mesi, Ospedale Oncologico M. Ascoli, Palermo, Italy; Professor A. Riccardi and Dr. P. Pugliese, Policlinico San Matteo, Pavia, Italy; Dr. G. Pavia and Dr. T. Porro, Ospedale Civile, Rho, Italy; Dr. F. Cognetti and Dr. P. Papaldo, Istituto Regina Elena, Rome, Italy; Dr. G. Gasparini and Dr. M.A. Castellana, Ospedale San Filippo Neri, Rome, Italy; Dr. M. Mattarei and Dr. S. Robbiati, Ospedale Civile Santa Maria delle Grazie, Rovereto, Italy; Professor A. Farris and Dr. G. Sanna, Istituto Clinica Medica, Sassari, Italy; Dr. C. Vucusa and Dr. M. Viglietta, Ospedale SS Annunziata, Savigliano, Italy; Dr. G. Fornari and Dr. A. Turletti, Ospedale Evangelico Valdese, Turin, Italy; Dr. E. Arnoldi, Azienda Ospedaliera Bolognini H. San Isidoro, Trescore Balneario, Italy; Dr. A. Richetti and Dr. M. Molteni, Azienda Ospedaliera Ospedale di Circolo e Fondazione Macchi, Varese, Italy. New Zealand: Mr. I. Campbell and Dr. R. Gannaway, Breast Care Centre, Waikato Hospital, Hamilton, New Zealand. Poland: Dr. J. Tujakowski and Dr. M. Osmanska, Regional Oncology Centre, Bydoszcz, Poland; Dr. P. Koralewski and Dr. M. Urbanska, Ludwick Rydygier Memorial Hospital, Krakow, Poland; Dr. B. Karczmarek-Borowska and Dr. B. Kukielka-Budny, Regional Oncology Centre, Lublin, Poland; Dr. M. Teresiak and Dr. P. Laski, Regional Oncology Centre, Poznan, Poland; Dr. M. Krzakowski and E. Pucula, Maria Sklodowska-Curie Memorial Oncology Centre, Warsaw, Poland. Portugal: Dr. A. Alcazar, Hospital Reynaldo dos Santos, Vila Franca de Xira, Portugal; Dr. O. Campos and Dr. I. Botto, Maternidade Bissaya Barreto, Coimbra, Portugal; Dr. O. Candeias and Dr. H. Ramires, Hospital de Sao Joao, Porto, Portugal; Dr. M. Chumbo, Hospital Condes de Castro Guimaraes, Cascais, Portugal; Dr. H. Gervasio, IPO–Hospital de Dia, Coimbra, Portugal; Dr. D. Jardim da Pena and Dr. R. Nabiço, Hospital de Sao Marcos, Braga, Portugal; Professor C. Oliveira and Dr. E. Abraul, Hospitais da Universidade de Coimbra, Coimbra, Portugal. Slovakia: Professor S. Spanik and Dr. I. Vochyanova, Onkologicky Ustav Sv. Alzbety, Bratislava, Slovakia; Dr. M. Wagnerova and Dr. I. Andrasina, FNsP L. Pasteura, Kosice, Slovakia. South Africa: Dr. A. Maxwell, 140 Chelmsford Road, Berea, South Africa; Professor L. Goedhals and Dr. L. Smith, National Hospital, Bloemfontein, South Africa; Professor I. Werner and Dr. E. Murray, Groote Schuur Hospital, Cape Town, South Africa; Dr. J. Apffelstaedt and Dr. I. Loubser, Tyerberg Hospital, Cape Town, South Africa; Dr. D. Hacking, Durban Oncology Centre, Durban, South Africa; Dr. G. Landers, Parklands Hospital, Durban, South Africa; Dr. D. Vorobiof, Sandton Oncology Centre, Johannesburg, South Africa. Spain: Dr. A. Barnadas, Hospital Germans Trias i Pujol, Badalona, Spain; Dra. C. Alonso Muñoz, Hospital Santa Cruz y San Pablo, Barcelona, Spain; Dr. J. Baselga and Dr. J. Tabernero, Hospital Vall D'Hebron, Barcelona, Spain; Dr. M. BeltrÁn and Dr. E. Canals, Hospital Josep Trueta, Gerona, Spain; Dr. S. Menjón, Hospital Virgen de las Nieves, Granada, Spain; Dra. L. Calvo, Hospital Juan Canalejo, La Coruña, Spain; Dr. J.R. Mel and Dr. G. Quintero, Hospital Xeral Calde, Lugo, Spain; Dr. G. Perez Manga and Dr. A. Alonso, Hospital Gregorio Marañón, Madrid, Spain; Dra. P. España and Dr. R. Cubedo Cervera, Hospital Puerta de Hierro, Madrid, Spain; Dra. C. Sánchez Martínez and Dr. M. Repolles Escarda,Hospital Ramón y Cajal, Madrid, Spain; Dr. P. Aramburo and Dr. J.E. Alés, Hospital Ruber Internacional, Madrid, Spain; Dr. J.J. Valerdi and Dr. M. Tejedor Gutierrez, Hospital de Navarra, Pamplona, Spain; Dr. M. Constenla and Dr. R. Garcia Arroyo, Hospital de Montecelo, Pontevedra, Spain; Dr. J. Lizon and Dra. C. Angeles, Hospital San Juan, San Juan de Alicante, Spain; Dr. J.M. Lopez-Vega, Hospital Marques de Valdecilla, Santander, Spain; Dra. D. Menendez, Hospital Provincial de Conxo, Santiago de Compostela, Spain; Dr. J.A. Moreno Nogueira and Dr. M.R. Borrego, Hospital Virgen del Rocio, Seville, Spain; Dr. J. Montalar and Dra. A. Santaballa, Hospital La Fe, Valencia, Spain; Dr. V. Guillem and Dr. A. Llombart, Instituto Valenciano Oncología, Valencia, Spain; Dr. G. Huidobro Vence and Dr. J. Casal, Hospital Meixoeiro, Vigo, Spain. Sweden: Dr. S.-Å. Olsson and Dr. L. Ryden, Sjukhuset, Ängelholm, Sweden; Dr. S. Rotstein and Dr. D. Pettersson-Sköld, Danderyds Sjukhus, Stockholm, Sweden; Dr. B. Börjesson, Länssjukhuset, Halmstad, Sweden; Dr. P.-E. Jönsson and Dr. M. Malmberg, Helsingborg Hospital, Helsingborg, Sweden; Dr. L. Lovén and Dr. I. Grybäck, Centralsjukhuset, Kristianstad, Sweden; Dr. C. Ingvar and Dr. P. Lindblom, University Hospital, Lund, Sweden; Dr. S.B. Holmberg, SU/Mölndal Hospital, Mölndal, Sweden; Dr. U. Nylén and Dr. E. Lidbrink, Karolinska Sjukhuset, Stockholm, Sweden; Dr. T. Fornander and Dr. G. Winblad, Södersjukhuset, Stockholm, Sweden; Dr. R. Fernstad and Dr. L. Löfgren, St. Görans Sjukhus, Stockholm, Sweden; Dr. T. Ambré and Dr. M. Nilsson, Centrallasarettet, Växjö, Sweden. The Netherlands: Dr. L. Siegenbeek van Heukelom, Medisch Centrum Alkmaar, Alkmaar, The Netherlands; Dr. R. Boom and Dr. D. van Geldere, Ziekenhuis Amstelveen, Amstelveen, The Netherlands; Dr. A. de Boer, IJsselland Ziekenhuis, Capelle a/d IJssel, The Netherlands; Dr. E. Maartense, Reinier de Graaf Gasthuis, Delft, The Netherlands; Dr. D. Halkema, Albert Schweitzer Ziekenhuis, Dordrecht, The Netherlands; Dr. C. Dijkhuis, Oosterschelde Ziekenhuis, Goes, The Netherlands; Dr. M. van Hennik, Beatrix Ziekenhuis, Gorinchem, The Netherlands; Dr. P. Willemse, Academisch Ziekenhuis Groningen, Groningen, The Netherlands; Dr. H. van Veelen and Dr. H. de Graaf, Medisch Centrum Leeuwarden, Leeuwarden, The Netherlands; Dr. E. Bruggink and Dr. L. Strobbe, Nijmeegs Interconfessioneel Ziekenhuis Canisius Wilhelmina, Nijmegen, The Netherlands; Dr. D. de Gooyer, Ziekenhuis Franciscus, Roosendaal, The Netherlands; Dr. J. Janssen, Ziekenhuis Franciscus, Roosendaal, The Netherlands; Dr. M. Leijs, Medisch Centrum Rijnmond Zuid, locatie Clara, Rotterdam, The Netherlands; Dr. J. Stouthard, Medisch Centrum Rijnmond Zuid, locatie Clara, Rotterdam, The Netherlands; Dr. J. Klijn and Dr. C. Seynaeve, Academisch Ziekenhuis Rotterdam, locatie Daniel den Hoed, Rotterdam, The Netherlands; Dr. F. Erdkamp, Maasland Ziekenhuis, Sittard, The Netherlands; Dr. F. Kauw, Albert Schweitzer Ziekenhuis, Sliedrecht, The Netherlands, Dr. A. van Reisen, Ziekenhuis Zeeuws Vlaanderen, locatie de Honte, Terneuzen, The Netherlands; Dr. C. van der Heul, St. Elisabeth Ziekenhuis, Tilburg, The Netherlands; Dr. J. Ruit, Vlietland Ziekenhuis, Vlaardingen, The Netherlands; Dr. L. Kerhofs, Ziekenhuis Walcheren, Vlissingen, The Netherlands; Dr. R. de Kan and Dr. R. Hellingman, Zweedse Rode Kruis Ziekenhuis, Zierikzee, The Netherlands; Dr. E. Trommel, Albert Schweitzer Ziekenhuis, Zwijndrecht, The Netherlands; Dr. J. Coenen, Isala Klinieken, locatie Sophia, Zwolle, The Netherlands. Turkey: Professor E. Baltali, Hacettepe University Oncology Hospital, Ankara, Turkey; Professor A. Aydiner, Istanbul University Oncology Institute, Istanbul, Turkey. United Kingdom: Dr. A. Hutcheon and Dr. T. Sarkar, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Mr. T. Bates and Mr. N. Griffiths, South Kent Hospitals NHS Trust, William Harvey Hospital, Ashford, United Kingdom; Mr. M. Carr, Cheviot & Wansbeck NHS Trust, Wansbeck General Hospital, Ashington, United Kingdom; Dr. C. Alcock, Stoke Mandeville Hospital NHS Trust, Aylesbury, United Kingdom; Dr. B. Lavery and Dr. E. Sugden, Horton Hospital, Radcliffe Hospitals NHS Trust, Banbury, United Kingdom; Professor N. Stuart and Mr. Derek Crawford, Gwynedd Hospital NHS Trust, Bangor, United Kingdom; Mr. A. Wilkinson and Mr. G. Odling-Smee, Belfast City Hospital NHS Trust, Belfast, United Kingdom; Dr. W. Abram and Dr. A. Patterson, Belfast City Hospital NHS Trust, Belfast, United Kingdom; Mr. A. Aukland and Dr. D. Spooner, Sandwell Healthcare NHS Trust, Sandwell District General Hospital, Birmingham, United Kingdom; Mr. H. Bishop and Mr. R. Salem, The Royal Bolton Hospital, Bolton, United Kingdom; Dr. T. Hickish and Mr. A. Skene, Royal Bournemouth & Christchurch NHS Trust, Royal Bournemouth Hospital, Bournemouth, United Kingdom; Dr. C. Bradley and Dr. Dennis Parker, Bradford Royal Infirmary, Bradford, United Kingdom; Mr. S. Cawthorn and Dr. M. Shere, Frenchay Healthcare NHS Trust, Frenchay Hospital, Bristol, United Kingdom; Dr. S. Goodman and Dr. E. Whipp, United Bristol Healthcare NHS Trust, Bristol Royal Infirmary, Bristol, United Kingdom; Dr. A. Moody, West Suffolk Hospital NHS Trust, Bury St. Edmunds, United Kingdom; Dr. C. Wilson and Dr. E. Cox, Addenbrooke's NHS Trust Hospital, Cambridge, United Kingdom; Professor R. Mansel and Ms. H. Sweetland, University Hospital of Wales NHS Trust, Cardiff, United Kingdom; Dr. P. Sauven and Dr. S. Chandrasekharan, Mid Essex Hospital Services NHS Trust, Chelmsford and Essex Centre, Chelmsford, United Kingdom; Mr. G. Layer, St. Peter's Hospital NHS Trust, Chertsey, United Kingdom; Dr. P. Murray and Ms. F. MacNeill, Essex Rivers Healthcare NHS Trust, Essex County Hospital, Colchester, United Kingdom; Mr. J. Fox, Castle Hill Hospital, Cottingham, United Kingdom; Mr. A. Ball, Crawley Horsham NHS Trust, Crawley Hospital, Crawley, United Kingdom; Mr. G. Rawsthorne, Mid Cheshire Hospitals NHS Trust, Leighton Hospital, Crewe, United Kingdom; Mr. R. Blunt, Dudley Group of Hospitals NHS Trust, Russells Hall Hospital, Dudley, United Kingdom; Dr. J. Dewar and Mr. A. Thompson, Ninewells Hospital & Medical School, Dundee, United Kingdom; Dr. W. Taylor and Mr. A. Cook, North Durham NHS Trust, Dryburn Hospital, Durham, United Kingdom; Dr. I. Kunkler, Western General Hospital, Edinburgh, United Kingdom; Dr. D. Cameron and Professor R. Leonard, Western General Hospital, Edinburgh, United Kingdom; Mr. W. Cunliffe and Mr. D. Browell, Gateshead Hospitals NHS Trust, Queen Elizabeth Hospital, Gateshead, United Kingdom; Professor W.D. George, Dr. A.N. Harnett, and Dr. C.T. Twelves, Western Infirmary, Glasgow, United Kingdom; Mr. D.C. Smith, Victoria Infirmary, Glasgow, United Kingdom; Mr. M. Kissin, The Royal Surrey County and St. Luke's NHS Trust, Royal Surrey County Hospital, Guildford, United Kingdom; Mr. V. Modgill and Mr. P. Surtees, Halifax Royal Infirmary, Halifax, United Kingdom; Mr. R. Knox, Harrogate District Hospital, Harrogate, United Kingdom; Dr. J. Joffe, Huddersfield Royal Infirmary, Huddersfield, United Kingdom; Dr. B. Lavery and Professor A. Harris, Oxford Radcliffe Hospital NHS Trust, John Radcliffe Hospital, Headington, United Kingdom; Mr. J. Nicholls and Mr. S. Raymond, St. Albans & Hemel Hempstead NHS Trust, St. Albans, United Kingdom; Dr. B. Lavery and Dr. N. Rowell, South Bucks NHS Trust, Wycombe General Hospital, High Wycombe, United Kingdom; Dr. J. LeVay and Mr. T. Archer, Ipswich Hospitals NHS Trust, Ipswich, United Kingdom; Mr. A. Nejim and Dr. I. Hutchinson, Airedale General Hospital, Keighley, United Kingdom; Mr. M. Lansdown and Dr. T. Perren, St. James's University Hospital, Leeds, United Kingdom; Mr. K. Horgan and Dr. D. Dodwell, Leeds General Infirmary, Leeds, United Kingdom; Mr. C. Holcombe, Royal Liverpool University Hospital NHS Trust, Royal Liverpool Hospital, Liverpool, United Kingdom; Mr. J. Rainey, St. John's Hospital at Howden, Livingston, United Kingdom; Dr. G. Howard, Western General Hospital, Edinburgh, United Kingdom; Mr. S. Holt and Mr. Y. Sharaiha, Llanelli & Dinefwr NHS Trust, Price Phillip Hospital, Llanelli, United Kingdom; Dr. J. Tobias and Dr. M. Gaze, University College London Hospitals NHS Trust, The Middlesex Hospital, London, United Kingdom; Dr. J. Mansi and Mr. N. Sacks, St. George's NHS Trust, St. George's Hospital, London, United Kingdom; Dr. C. Coulter and Dr. S. Stewart, St. Mary's NHS Trust, St. Mary's Hospital, London, United Kingdom; Dr. A. Jones and Mr. T. Davidson, Royal Free Hampstead NHS Trust, The Royal Free Hospital, London, United Kingdom; Mr. Sainsbury, University College London, London, United Kingdom; Dr. A. Jones and Mr. A. Wilson, Whittington Hospital NHS Trust, London, United Kingdom; Professor I. Smith and Mr. G. Gui, The Royal Marsden Hospital NHS Trust, The Royal Marsden Hospital, London, United Kingdom; Mr. D. Matheson, Macclesfield District General Hospital, Macclesfield, United Kingdom; Professor A. Howell and Dr. A. Stewart, Christie Hospital, Manchester, United Kingdom; Dr. L. Barr and Dr. N. Bundred, Withington Hospital, Manchester, United Kingdom; Ms. P. Durning and Mr. A. Clason, James Cook University Hospital, Middlesbrough, United Kingdom; Mr. A. Mitchell and Mr. R. Souter, Milton Keynes General Hospital, Milton Keynes, United Kingdom; Mr. C. Griffith and Mr. A. Griffiths, Newcastle Hospitals NHS Trust, Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom; Dr. C. Gaffney, Glan Hafren NHS Trust, Royal Gwent Hospital, Newport, United Kingdom; Mr. M. Stokes, Daisy Hill Hospital, Newry, United Kingdom; Mr. J. Dawson and Mr. S. Powis, Northampton General Hospital NHS Trust, Northampton, United Kingdom; Mr. I. Goulbourne, North Tyneside Health Care NHS Trust, North Tyneside General Hospital, North Shields, United Kingdom; Dr. A. Makris and Dr. E. Maher, Mount Vernon & Watford Hospitals NHS Trust, Mount Vernon Hospital, Northwood, United Kingdom; Professor J.R. Robertson and Professor R. Blamey, Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Mr. R. Nangalia and Mr. H. Bishop, George Eliot Hospital NHS Trust, Nuneaton, United Kingdom; Mr. I. McIntosh, Royal Oldham Hospital, Oldham, United Kingdom; Mr. D. Pinto, Sperrin Lakeland Health & Social Care Trust, Tyrone County Hospital, Omagh, United Kingdom; Dr. B. Lavery and Dr. A. Jones, Oxford Radcliffe Hospital NHS Trust, The Churchill Hospital, Oxford, United Kingdom; Mr. R. Watkins and Dr. S. Prance, Plymouth Hospital NHS Trust, Derriford Hospital, Plymouth, United Kingdom; Dr. C. Tyrrell and Dr. P. Macleod, Plymouth Hospital NHS Trust, Derriford Hospital, Plymouth, United Kingdom; Mr. C. Yiangou and Professor P. Perry, Portsmouth Hospital NHS Trust, Portsmouth, United Kingdom; Mr. C. Humphrey, Birch Hill Hospital,Rochdale, United Kingdom; Dr. M. Quigley, Havering Hospitals NHS Trust, Oldchurch Hospital, Romford, United Kingdom; Ms. Z. Saad and Dr. E. Hoare, Salford Royal Hospitals NHS Trust, Hope Hospital, Salford, United Kingdom; Professor R. Coleman and Mr. S. Kohlhardt, Weston Park Hospital, Sheffield, United Kingdom; Mr. B. Harrison, Northern General Hospital, Sheffield, United Kingdom; Dr. R. Agrawal, Royal Shrewsbury NHS Trust, Shrewsbury, United Kingdom; Mr. P. Forouhi, Ealing Hospital NHS Trust, Ealing Hospital, Southall, United Kingdom; Dr. P. Canney, Stirling Royal Infirmary, Stirling, United Kingdom; Mr. P. England, Stepping Hill Hospital, Stockport, United Kingdom; Mr. C. Hennessy and Mr. A. Peel, North Tees General Hospital, Stockton-on-Tees, United Kingdom; Mr. E. Hoare, Trafford General Hospital, Trafford, United Kingdom; Dr. S. Kelly and Dr. K. Stepp, Royal Cornwall Hospitals NHS Trust, Treliske Hospital, Truro, United Kingdom; Dr. D. Sebag-Montefiore, Pinderfield Hospital, Wakefield, United Kingdom; Dr. R. Grieve and Mr. T. Waterworth, Walsgrave Hospitals NHS Trust, Walsgrave, United Kingdom; Mr. G. Copeland, Warrington Hospital NHS Trust, Warrington, United Kingdom; Dr. D. Jones, South Warwickshire General Hospitals NHS Trust, Warwick, United Kingdom; Dr. A. Robinson and Dr. C. Trask, Southend Healthcare NHS Trust Hospital, Westcliffe-on-Sea, United Kingdom; Professor P. Barrett-Lee, Velindre NHS Trust Hospital, Whitchurch, United Kingdom; Mr. R. Rainsbury and Dr. V. Hall, Royal Hampshire County Hospital, Winchester & Eastleigh Healthcare NHS Trust, Winchester, United Kingdom; Mr. D. Berstock and Dr. R. Errington, Wirral Hospital NHS Trust, Wirral, United Kingdom; Dr. D. Fairlamb, Royal Wolverhampton Hospitals NHS Trust, New Cross Hospital, Wolverhampton, United Kingdom; Mr. A. Salman and Mr. A. Johri, Worthing Southlands Hospital NHS Trust, Worthing Hospital, Worthing, United Kingdom; Dr. S. Goodman and Dr. G. Sparrow, East Somerset NHS Trust, Yeovil District Hospital, Yeovil, United Kingdom; Mr. S. Nicholson, York District Hospital, York, United Kingdom. United States of America: Dr. A. Mangalik, University of New Mexico Cancer Research and Treatment Center, Albuquerque, New Mexico; Dr. S.J. Yee, Suite 304, Arcadia, California; Dr. J.M. Feigert, Arlington Fairfax Hematology/Oncology, Arlington, Virginia; Dr. R.O. Kerr, Southwest Regional Cancer Center, Austin, Texas; Dr. K. Tkaczuk, University of Maryland Cancer Center, Baltimore, Maryland; Dr. M. Thant, Hematology/Oncology Associates, Baltimore, Maryland; Dr. C.E. Hartz, Eastern Maine Medical Center, Cancer Care of Maine, Bangor, Maine; Dr. G.P. Miletello, Hematology/Oncology Clinic, Baton Rouge, Lousiana; Dr. W.J. Popovic, Illinois Oncology Ltd., Belleville, Illinois; Dr. D.B. Myers, Billings Interhospital Oncology Project, Billings, Montana; Dr. M.R. Thomas, Mid Dakota Clinic, Bismarck, North Dakota; Dr. A.J. Koletsky, Comprehensive Cancer Center, Boca Raton, Florida; Dr. E.G. Levine, Roswell Park Cancer Institute, Buffalo, New York; Dr. C.F. White, Lahey Clinic, Department of Medical Oncology, Burlington, Massachusetts; Dr. G. Grana, Cooper University Hospital, Camden, New Jersey; Dr. K.E. Weeman, Aultman Hospital Cancer Research Program, Canton, Ohio; Dr. L.L. Schlabach, University Oncology Associates, Chattanooga, Tennessee; Dr. S.G. Taylor, Illinois Masonic Cancer Center, Chicago, Illinois; Dr. P. Silverman, University Hospitals of Cleveland, Cleveland, Ohio; Dr. D.L. Headley, The Oncology Clinic PC, Colorado Springs, Colorado; Dr. M.F. Gonzalez, University of South Carolina School of Medicine, Columbia, South Carolina; Dr. L.R. Laufman, Columbus Community Clinical Oncology Program, Columbus, Ohio; Dr. J.L. Blum, US Oncology Services, Dallas, Texas; Dr. H.S. Shaw (former principal investigator, Dr. L.N. Harris), Duke University Medical Center, Durham, North Carolina; Dr. N. Dimitrov (former principal investigator, Dr. D. MacDonald), Michigan State University, East Lansing, Michigan; Dr. E.T. O'Brien, The Regional Cancer Center, Erie, Pennsylvania; Dr. G.Y. Locker, Evanston Northwestern Healthcare, Kellogg Cancer Care Center, Evanston, Illinois; Dr. N.J. Robert, Inova/Fairfax Hospital, Falls Church, Virginia; Dr. M.S. Rubin, Florida Cancer Specialists, Fort Myers, Florida; Dr. G.R. Justice, Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, California; Dr. T.J. O'Rourke (former principal investigator, Dr. J.R. Borst), Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan; Dr. A.U. Buzdar, M.D. Anderson Cancer Center, Houston, Texas; Dr. J.K. Hon, Comprehensive Cancer Care Institute, Huntsville, Alabama; Dr. R.H. Clark, Hematology/Oncology Associates, Jackson, Mississippi; Dr. H.B. Sher, Jacksonville Oncology Group, Jacksonville, Florida; Dr. K.B. Pendergrass, Kansas City Internal Medicine, Kansas City, Missouri; Dr. A.M. Grossman, Knoxville Hematology/Oncology, Knoxville, Tennessee; Dr. H.P. DeGreen, Lancaster Cancer Center Ltd., Lancaster, Pennsylvania; Dr. R. Kosierowski, North Penn Hospital, Lansdale, Pennsylvania; Dr. H.J. Allen, Southwest Cancer Clinic, Las Vegas, Nevada; Dr. J.D. Conroy (former principal investigator, Dr. M.A. Simmonds), Central Pennsylvania Hematology and Medical Oncology Associates, Lemoyne, Pennsylvania; Dr. J.J. Sternberg, Clinical Investigation Specialist, Suite 300, Searcy Building, Little Rock, Arkansas; Dr. G.P. Sarna, Cedars-Sinai Comprehensive Cancer Center, Los Angeles, California; Dr. L. Bhupalam (former principal investigator, Dr. G.C. Michelson), James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky; Dr. M.H. Ward, Medical Arts Clinic, Lubbock, Texas; Dr. P.T. Silberstein, North Iowa Mercy Health Center, Mason City, Iowa; Dr. P.V. Pickens, Abington Hematology-Oncology, Meadowbrook, Pennsylvania; Dr. M.A. Schwartz, Comprehensive Cancer Center, Miami Beach, Florida; Dr. J. Singson, Oncology Associates SC, Milwaukee, Wisconsin; Dr. J.G. Schneider, Winthrop University, Mineola, New York; Dr. M.M. Oken, Virginia Piper Cancer Institute, Minneapolis, Minnesota; Dr. M.W. Meshad, Providence Hospital, Mobile, Alabama; Dr. F.A. Greco, Sarah Cannon Cancer Center, Nashville, Tennessee; Dr. M.J. Guarino, Christiana Hospital, Newark, Delaware; Dr. K.K. Boatman, INTERGIS Oncology Services, Oklahoma City, Oklahoma; Dr. J.A. Mailliard, Creighton Cancer Center, Omaha, Nebraska; Dr. A.S. Kelley, Ventura County Hematology-Oncology, Oxnard, California; Dr. D.W. Northfelt (former principal investigator, Dr. E.S. Camacho), Desert Hospital Comprehensive Cancer Center, Palm Springs, California; Dr. R.A. Hirsch, Comprehensive Cancer Research Group, Pembroke Pines, Florida; Dr. B.R. Piccone, The Care Group PC, Philadelphia, Pennsylvania; Dr. M.S. Roberts, Hematology & Oncology Associates Ltd., Phoenix, Arizona; Dr. J.I. Spector, Berkshire Hematology Oncology, Pittsfield, Massachusetts; Dr. N. Tirumali (former principal investigator, Dr. A.G. Glass), Kaiser Permanente, Central Interstate Medical Office, Portland, Oregon; Dr. M.A. Deutsch, Raleigh Hematology Oncology, Raleigh, North Carolina; Dr. D.M. Sahasrabudhe, University of Rochester Cancer Center, Rochester, New York; Dr. P. Bushunow (former principal investigator, Dr. M. Brower), Rochester General Hospital, Rochester, New York; Dr. T.J. Woodlock (former principal investigator, Dr. K.J. Pandya), St. Mary's Hospital, Rochester, New York; Dr. W.R. Edwards, The Cancer Center, Rockford Clinic, Rockford, Illinois; Dr. I.A. Jaiyesimi, Cancer Care Associates PC, Royal Oak, Michigan; Dr. F.C. Kass, Santa Barbara Hematology-Oncology Medical Group, Santa Barbara, California; Dr. L.W. Keiser, Redwood Regional Medical Group, Santa Rosa, California; Dr. G.V. Burton, Louisiana State University Medical Center, Shreveport, Louisiana; Dr. J.C. Michalak, Siouxland Hematology/Oncology Associates, Sioux City, Iowa; Dr. M.S. McHale, University Physicians Oncology Clinic, Sioux Falls, South Dakota; Dr. J.R. Goodman, Providence Hospital, Southfield, Michigan; Dr. P.D. Byeff, Department of Hematology/Oncology, Bradley Memorial Hospital, Southington, Connecticut; Dr. K.L. Hoelzer, Springfield Clinic, Springfield, Illinois; Dr. E.P. Lester, Oncology Care Associates PLLC, St. Joseph, Michigan; Dr. A.P. Lyss, Missouri Baptist Cancer Center, St. Louis, Missouri; Dr. M.E. Woodson, Hematology Oncology Consultants Inc., St. Louis, Missouri; Dr. H.S. Puc, Hematology and Oncology Associates, Syracuse, New York; Dr. F. Senecal, Hematology Oncology Northwest PC, Tacoma, Washington; Dr. J. Horton, Moffitt Cancer Center & Research Institute, Tampa, Florida; Dr. R.R. Young, Scott & White Memorial Hospital, Temple, Texas; Dr. I.S. Lowenthal, Northwestern Connecticut Oncology and Hematology Associates, Torrington, Connecticut; Dr. H.B. Nevinny, Cancer Treatment Center of Tulsa, Tulsa, Oklahoma; Dr. E.P. Gelman (former principal investigators, Dr. D.F. Hayes and Dr. M.J.C. Ellis), Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC; Dr. M.A. Vukelich, Kettle Moraine Oncology SC, West Bend, Wisconsin; Dr. K. Seetharaman (former principal investigator, Dr. L.L. Stolbach), St. Vincent's Hospital, Worcester, Massachusetts.

  6. ††

    Michael Baum, Aman Buzdar, Jack Cuzick, John Forbes, Joan Houghton, Anthony Howell, and Jan Klijn all have received travel awards and honoraria from AstraZeneca for the purposes of attending ATAC Trial Steering Committee meetings or presenting the results of the ATAC trial. Michael Baum has provided independent paid consultation on aspects relating to the ATAC trial. Jack Cuzick is a principal investigator on an unrestricted educational grant awarded to Cancer Research UK by AstraZeneca for the evaluation of aromatase inhibitors in breast cancer prevention. Tarek Sahmoud is an employee of AstraZeneca and holds stock in the company. Joan Houghton holds a contract with Astra Zeneca for operational management and to support some of the monitoring of the trial.

  7. ‡‡

    Fax: (011) 44 0 207 679 9678

*Department of Surgery, Charles Bell House, 67-73 Riding House Street, London W1W 7EJ, UK

Publication History

  1. Issue published online: 22 OCT 2003
  2. Article first published online: 29 SEP 2003
  3. Manuscript Accepted: 30 JUN 2003
  4. Manuscript Revised: 23 JUN 2003
  5. Manuscript Received: 13 MAY 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (120K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Christos Markopoulos, Evagelos Tzoracoleftherakis, Dimitrios Koukouras, Basileios Venizelos, Vasilios Zobolas, John Misitzis, Grigorios Xepapadakis, Helen Gogas, Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial, Journal of Cancer Research and Clinical Oncology, 2012,

    CrossRef

  2. 2
    Serdar E. Bulun, Dong Chen, Irene Moy, David C Brooks, Hong Zhao, Aromatase, breast cancer and obesity: a complex interaction, Trends in Endocrinology & Metabolism, 2012, 23, 2, 83

    CrossRef

  3. 3
    J. M. Rae, S. Drury, D. F. Hayes, V. Stearns, J. N. Thibert, B. P. Haynes, J. Salter, I. Sestak, J. Cuzick, M. Dowsett, CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients, JNCI Journal of the National Cancer Institute, 2012, 104, 6, 452

    CrossRef

  4. 4
    Isaac Schmale, Stephen Liu, Jessica Rayhanabad, Christy A. Russell, Stephen F. Sener, Ductal carcinoma in situ (DCIS) of the breast: Perspectives on biology and controversies in current management, Journal of Surgical Oncology, 2012, 105, 2
    Direct Link:
  5. 5
    Hiroyuki Takei, Shozo Ohsumi, Kojiro Shimozuma, Megumi Takehara, Kimito Suemasu, Yasuo Ohashi, Yasuo Hozumi, Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04), Breast Cancer Research and Treatment, 2012, 133, 1, 227

    CrossRef

  6. 6
    Ewa Mrózek, Rachel Layman, Bhuvaneswari Ramaswamy, Larry Schaaf, Xiaobai Li, Susan Ottman, Charles L. Shapiro, Phase II Trial of Exemestane in Combination With Fulvestrant in Postmenopausal Women With Advanced, Hormone-Responsive Breast Cancer, Clinical Breast Cancer, 2012, 12, 2, 151

    CrossRef

  7. 7
    Gerardus W.J. Frederix, Johan L. Severens, Anke M. Hövels, Jan A.M. Raaijmakers, Jan H.M. Schellens, Reviewing the Cost-Effectiveness of Endocrine Early Breast Cancer Therapies: Influence of Differences in Modeling Methods on Outcomes, Value in Health, 2012, 15, 1, 94

    CrossRef

  8. 8
    Alison E. Obr, Dean P. Edwards, The biology of progesterone receptor in the normal mammary gland and in breast cancer, Molecular and Cellular Endocrinology, 2012, 357, 1-2, 4

    CrossRef

  9. 9
    Ivana Sestak, Michelle Harvie, Anthony Howell, John F. Forbes, Mitch Dowsett, Jack Cuzick, Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer, Breast Cancer Research and Treatment, 2012,

    CrossRef

  10. 10
    Jane Flanagan, Loren N. Winters, Karleen Habin, Barbara Cashavelly, Women's Experiences With Antiestrogen Therapy to Treat Breast Cancer, Oncology Nursing Forum, 2012, 39, 1, 70

    CrossRef

  11. 11
    K B Lundin, M Henningson, M Hietala, C Ingvar, C Rose, H Jernström, Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients, British Journal of Cancer, 2011, 105, 11, 1676

    CrossRef

  12. 12
    Jeanne S. Mandelblatt, Gheorghe Luta, Marilyn L. Kwan, Solomon B. Makgoeng, Isaac J. Ergas, Janise M. Roh, Barbara Sternfeld, Lucile L. Adams-Campbell, Lawrence H. Kushi, Associations of physical activity with quality of life and functional ability in breast cancer patients during active adjuvant treatment: the Pathways Study, Breast Cancer Research and Treatment, 2011, 129, 2, 521

    CrossRef

  13. 13
    Keo Tabane, Daniel A. Vorobiof, Bone Targeted Therapies in Early Breast Cancer, Current Treatment Options in Oncology, 2011, 12, 4, 412

    CrossRef

  14. 14
    Federica Tomao, GianPaolo Spinelli, Patrizia Vici, Giovanni Codacci Pisanelli, GianLuca Cascialli, Luigi Frati, PierLuigi Benedetti Panici, Silverio Tomao, Current role and safety profile of aromatase inhibitors in early breast cancer, Expert Review of Anticancer Therapy, 2011, 11, 8, 1253

    CrossRef

  15. 15
    P. S. Hall, C. McCabe, R. C. Stein, D. Cameron, Economic Evaluation of Genomic Test-Directed Chemotherapy for Early-Stage Lymph Node-Positive Breast Cancer, JNCI Journal of the National Cancer Institute, 2011, 104, 1, 56

    CrossRef

  16. 16
    Paul E. Goss, James N. Ingle, José E. Alés-Martínez, Angela M. Cheung, Rowan T. Chlebowski, Jean Wactawski-Wende, Anne McTiernan, John Robbins, Karen C. Johnson, Lisa W. Martin, Eric Winquist, Gloria E. Sarto, Judy E. Garber, Carol J. Fabian, Pascal Pujol, Elizabeth Maunsell, Patricia Farmer, Karen A. Gelmon, Dongsheng Tu, Harriet Richardson, Exemestane for Breast-Cancer Prevention in Postmenopausal Women, New England Journal of Medicine, 2011, 364, 25, 2381

    CrossRef

  17. 17
    Faryal Sardar Ali Mirza, Management of Bone Disease in Patients Undergoing Hormonal Therapy for Breast Cancer, Endocrinology & Metabolism Clinics of North America, 2011, 40, 3, 549

    CrossRef

  18. 18
    Julián Iturbe, José Pablo Leone, Ariel Zwenger, Carlos Vallejo, Bernardo Leone, Neoadjuvant endocrine treatment of women with breast cancer, Oncology Reviews, 2011, 5, 3, 157

    CrossRef

  19. 19
    Anita K. Dunbier, Lesley-Ann Martin, Mitch Dowsett, New and translational perspectives of oestrogen deprivation in breast cancer, Molecular and Cellular Endocrinology, 2011, 340, 2, 137

    CrossRef

  20. 20
    Bethany Lynch, Judith A. Paice, Pain and Palliative Care Needs of Cancer Survivors, Journal of Hospice & Palliative Nursing, 2011, 13, 4, 202

    CrossRef

  21. 21
    Muhammad Younus, Michelle Kissner, Lester Reich, Nicola Wallis, Putting the Cardiovascular Safety of Aromatase Inhibitors in Patients with Early Breast Cancer into Perspective, Drug Safety, 2011, 34, 12, 1125

    CrossRef

  22. 22
    Juan Lao Romera, Teresa de Jesús Puertolas Hernández, Ignacio Peláez Fernández, Teresa Sampedro Gimeno, Roberto Fernández Martínez, Isaura Fernández Pérez, Vega Iranzo González Cruz, José Juan Illarramendi Mañas, Salvador Garcerá Juan, Eva María Ciruelos Gil, Update on adjuvant hormonal treatment of early breast cancer, Advances in Therapy, 2011, 28, S6, 1

    CrossRef

  23. 23
    Antonella L. Rastelli, Marie E. Taylor, Feng Gao, Reina Armamento-Villareal, Shohreh Jamalabadi-Majidi, Nicola Napoli, Matthew J. Ellis, Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial, Breast Cancer Research and Treatment, 2011, 129, 1, 107

    CrossRef

  24. 24
    Rajeev Jain, Vikas, Keisham Radhapyari, Voltammetric quantification of tamoxifen, Drug Testing and Analysis, 2011, 3, 10
    Direct Link:
  25. 25
    Paul TR Thiruchelvam, William E. Svensson, John Lynn, Gynaecology, 2011,

    CrossRef

  26. 26
    Joseph A. Lorenzo, Ernesto Canalis, Lawrence G. Raisz, Williams Textbook of Endocrinology, 2011,

    CrossRef

  27. 27
    Rachel A. Freedman, Eric P. Winer, Adjuvant therapy for postmenopausal women with endocrine-sensitive breast cancer, The Breast, 2010, 19, 2, 69

    CrossRef

  28. 28
    Mette L. Josefsson, Samuel J. Leinster, Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: Meta-analyses of monotherapy, sequenced therapy and extended therapy, The Breast, 2010, 19, 2, 76

    CrossRef

  29. 29
    Gail P. Risbridger, Ian D. Davis, Stephen N. Birrell, Wayne D. Tilley, Breast and prostate cancer: more similar than different, Nature Reviews Cancer, 2010, 10, 3, 205

    CrossRef

  30. 30
    Mary Ann Zalewski, Susan Beikman, Shannon Ferrari, Kathleen Slavish, Margaret Rosenzweig, Breast Cancer Follow-Up: Strategies for Successful Collaboration between Cancer Care Specialists and Primary Care Providers, The Journal for Nurse Practitioners, 2010, 6, 6, 452

    CrossRef

  31. 31
    Sekwon Jang, Young Kwang Chae, Tufia Haddad, Navneet S. Majhail, Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review, Breast Cancer Research and Treatment, 2010, 121, 2, 273

    CrossRef

  32. 32
    Michael Lipsitz, Thomas E. Delea, Amy Guo, Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer, Current Medical Research and Opinion, 2010, 26, 10, 2315

    CrossRef

  33. 33
    Hye-Jae Lee, Tae-Jin Lee, Bong-Min Yang, Junwon Min, Cost-Effectiveness Analysis of Adjuvant Hormonal Treatments for Women with Postmenopausal Hormone-Receptor Positive Early Breast Cancer in the Korean Context, Journal of Breast Cancer, 2010, 13, 3, 286

    CrossRef

  34. 34
    Mary Beth O’Connell, Laura M Borgelt, Susan K Bowles, Sheryl F Vondracek, Drug-induced osteoporosis in the older adult, Aging Health, 2010, 6, 4, 501

    CrossRef

  35. 35
    Emilio Bria, Paolo Carlini, Federica Cuppone, Vanja Vaccaro, Michele Milella, Francesco Cognetti, Early recurrence risk: aromatase inhibitors versus tamoxifen, Expert Review of Anticancer Therapy, 2010, 10, 8, 1239

    CrossRef

  36. 36
    Christos J Markopoulos, Alexandra K Tsaroucha, Helen J Gogas, Effect of aromatase inhibitors on the lipid profile of postmenopausal breast cancer patients, Clinical Lipidology, 2010, 5, 2, 245

    CrossRef

  37. 37
    T. Delozier, Hormonothérapie du cancer du sein, Journal de Gynécologie Obstétrique et Biologie de la Reproduction, 2010, 39, 8, F71

    CrossRef

  38. 38
    Aditya Bardia, Vered Stearns, Pharmacogenomics of Tamoxifen: Ready for Prime Time?, Current Breast Cancer Reports, 2010, 2, 1, 32

    CrossRef

  39. 39
    B.L. Clarke, Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer, Yearbook of Endocrinology, 2010, 2010, 234

    CrossRef

  40. 40
    Saby George, Andrew Brenner, John Sarantopoulos, Ronald M. Bukowski, RANK Ligand: Effects of Inhibition, Current Oncology Reports, 2010, 12, 2, 80

    CrossRef

  41. 41
    Jean-Marc Nabholtz, Marie-Ange Mouret-Reynier, Xavier Durando, Isabelle Praag, Béatrice Nayl, Jean-Pierre Ferriere, Philippe Chollet, Role of aromatase inhibitors in the upfront adjuvant hormonal therapy of postmenopausal patients with breast cancer, Indian Journal of Surgical Oncology, 2010, 1, 1, 19

    CrossRef

  42. 42
    Hatem A Azim Jr, Martine J Piccart, Simultaneous targeting of estrogen receptor and HER2 in breast cancer, Expert Review of Anticancer Therapy, 2010, 10, 8, 1255

    CrossRef

  43. 43
    Daniel Prieto-Alhambra, M. Kassim Javaid, Sonia Servitja, Nigel K. Arden, Maria Martinez-García, Adolfo Diez-Perez, Joan Albanell, Ignasi Tusquets, Xavier Nogues, Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study, Breast Cancer Research and Treatment, 2010, 125, 3, 869

    CrossRef

  44. 44
    Melissa A. Crosby, David W. Chang, Aesthetic and Reconstructive Surgery of the Breast, 2010,

    CrossRef

  45. 45
    Meyler's Side Effects of Drugs in Cancer and Immunology, 2010,

    CrossRef

  46. 46
    Sean R. Duffy, Wolfgang Distler, Anthony Howell, Jack Cuzick, Michael Baum, A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial, American Journal of Obstetrics and Gynecology, 2009, 200, 1, 80.e1

    CrossRef

  47. 47
    Yasuaki Sagara, Shoichiro Kosha, Shinichi Baba, Fumiko Dokiya, Shugo Tamada, Yoshiaki Sagara, Yoshito Matsuyama, Yasuyo Ohi, Mitsutake Ando, Yoshiaki Rai, Yoshiatsu Sagara, Tsutomu Douchi, Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients, Breast Cancer, 2009, 17, 3, 212

    CrossRef

  48. 48
    Marc P.J. McCafferty, Nuala A. Healy, Michael J. Kerin, Breast cancer subtypes and molecular biomarkers, Diagnostic Histopathology, 2009, 15, 10, 485

    CrossRef

  49. 49
    Paul E. Goss, Shangle Qi, Haiqing Hu, Comparing the effects of atamestane, toremifene and tamoxifen alone and in combination, on bone, serum lipids and uterus in ovariectomized rats, The Journal of Steroid Biochemistry and Molecular Biology, 2009, 113, 3-5, 233

    CrossRef

  50. 50
    Seema Harichand-Herdt, Amelia Zelnak, Ruth O’Regan, Endocrine therapy for the treatment of postmenopausal women with breast cancer, Expert Review of Anticancer Therapy, 2009, 9, 2, 187

    CrossRef

  51. 51
    Emma D. Deeks, Lesley J. Scott, Exemestane, Drugs, 2009, 69, 7, 889

    CrossRef

  52. 52
    Robert Clarke, Ayesha N. Shajahan, Rebecca B. Riggins, Younsook Cho, Anatasha Crawford, Jianhua Xuan, Yue Wang, Alan Zwart, Ruchi Nehra, Minetta C. Liu, Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells, The Journal of Steroid Biochemistry and Molecular Biology, 2009, 114, 1-2, 8

    CrossRef

  53. 53
    Stephanie L. Hines, Betty Mincey, Todor Dentchev, Jeff A. Sloan, Edith A. Perez, David B. Johnson, Paul L. Schaefer, Steve Alberts, Heshan Liu, Stephen Kahanic, Miroslaw A. Mazurczak, Daniel A. Nikcevich, Charles L. Loprinzi, Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC, Breast Cancer Research and Treatment, 2009, 117, 3, 603

    CrossRef

  54. 54
    M. Katherine Hoy, Barbara L. Winters, Rowan T. Chlebowski, Constantina Papoutsakis, Alice Shapiro, Michele P. Lubin, Cynthia A. Thomson, Mary B. Grosvenor, Trisha Copeland, Elyse Falk, Kristina Day, George L. Blackburn, Implementing a Low-Fat Eating Plan in the Women's Intervention Nutrition Study, Journal of the American Dietetic Association, 2009, 109, 4, 688

    CrossRef

  55. 55
    Lee S. Schwartzberg, Patrick Cobb, Frank Senecal, David Henry, Kimary Kulig, Mark S. Walker, Arthur C. Houts, Edward J. Stepanski, Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer, The Breast, 2009, 18, 2, 78

    CrossRef

  56. 56
    Bin Su, Shiuan Chen, Lead optimization of COX-2 inhibitor nimesulide analogs to overcome aromatase inhibitor resistance in breast cancer cells, Bioorganic & Medicinal Chemistry Letters, 2009, 19, 23, 6733

    CrossRef

  57. 57
    K. Hancke, M. Denkinger, C. Kurzeder, R. Kreienberg, Mammakarzinom: die ältere Patientin, Der Gynäkologe, 2009, 42, 9, 675

    CrossRef

  58. 58
    Susan Hong, Aarati Didwania, Olufunmilayo Olopade, Pamela Ganschow, The Expanding Use of Third-Generation Aromatase Inhibitors: What the General Internist Needs to Know, Journal of General Internal Medicine, 2009, 24, S2, 383

    CrossRef

  59. 59
    S. Samphao, J.M. Eremin, M. El-Sheemy, O. Eremin, Treatment of established breast cancer in post-menopausal women: Role of aromatase inhibitors, The Surgeon, 2009, 7, 1, 42

    CrossRef

  60. 60
    Markus Joerger, Beat Thürlimann, Update of the BIG 1–98 Trial: Where do we stand?, The Breast, 2009, 18, S78

    CrossRef

  61. 61
    Nancy L. Waltman, Carol D. Ott, Janice J. Twiss, Gloria J. Gross, Ada M. Lindsey, Vitamin D Insufficiency and Musculoskeletal Symptoms in Breast Cancer Survivors on Aromatase Inhibitor Therapy, Cancer Nursing, 2009, 32, 2, 143

    CrossRef

  62. 62
    Mindy Goldman, Kim OʼHair, Womenʼs Health, Breast Health, Obstetrical & Gynecological Survey, 2009, 64, 7, 469

    CrossRef

  63. 63
    Meyler's Side Effects of Endocrine and Metabolic Drugs, 2009,

    CrossRef

  64. 64
    Kimberly Stegmaier, William R. Sellers, Oncology of Infancy and Childhood, 2009,

    CrossRef

  65. 65
    Tristin Abair, Jennifer Klem, Susan Peck, Joyce O'Shaughnessy, 2007 Highlights from: The 2007 San Antonio Breast Cancer Symposium San Antonio, TX December 13-16, 2007, Clinical Breast Cancer, 2008, 8, 1, 26

    CrossRef

  66. 66
    Beatrice J. Edwards, Athena Samaras, June M. McKoy, Simone Boyle, Charles L. Bennett, AIs: implications for fractures in perimenopausal women with breast cancer, Community Oncology, 2008, 5, 11, 625

    CrossRef

  67. 67
    Mary K. Hughes, Alterations of Sexual Function in Women With Cancer, Seminars in Oncology Nursing, 2008, 24, 2, 91

    CrossRef

  68. 68
    Kimberly L. Blackwell, Are all aromatase inhibitors alike?, Breast Cancer Research and Treatment, 2008, 112, S1, 35

    CrossRef

  69. 69
    J.M. Nabholtz, Aromatase inhibitors in the management of early breast cancer, European Journal of Surgical Oncology (EJSO), 2008, 34, 11, 1199

    CrossRef

  70. 70
    Nancy L. Waltman, Carol D. Ott, Janice J. Twiss, Gloria J. Gross, Ada M. Lindsey, Timothy E. Moore, Bone Mineral Density and Bone Turnover in Postmenopausal Women Treated for Breast Cancer, Cancer Nursing, 2008, 31, 3, 182

    CrossRef

  71. 71
    Ivana Sestak, Jack Cuzick, Breast cancer chemoprevention, Oncology Reviews, 2008, 2, 4, 223

    CrossRef

  72. 72
    Aurelio B Castrellon, Stefan Glück, Chemoprevention of breast cancer, Expert Review of Anticancer Therapy, 2008, 8, 3, 443

    CrossRef

  73. 73
    Fauzia Rana, Shalin Shah, Comparing aromatase inhibitors and tamoxifen as neoadjuvant therapy for breast cancer, Community Oncology, 2008, 5, 6, 301

    CrossRef

  74. 74
    Jennifer Eng-Wong, Jo Anne Zujewski, Current NCI-sponsored Cooperative Group trials of endocrine therapies in breast cancer, Cancer, 2008, 112, S3
    Direct Link:
  75. 75
    Hirotaka Iwase, Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer, Breast Cancer, 2008, 15, 4, 278

    CrossRef

  76. 76
    Jack Cuzick, IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole, Expert Review of Anticancer Therapy, 2008, 8, 9, 1377

    CrossRef

  77. 77
    Nikolay V. Dimitrov, Sunil Nagpal, Shalini Chitneni, Management of male breast cancer, Oncology Reviews, 2008, 2, 1, 44

    CrossRef

  78. You have free access to this content78
    Marcia Valenzuela, Thomas B. Julian, Neo-Adjuvant Hormonal Therapy, The Breast Journal, 2008, 14, 3
    Direct Link:
  79. 79
    Agustí Barnadas, Miguel Gil, Pedro Sánchez-Rovira, Antonio Llombart, Encarna Adrover, Laura G. Estevez, Juan de la Haba, Lourdes Calvo, Neoadjuvant endocrine therapy for breast cancer: past, present and future, Anti-Cancer Drugs, 2008, 19, 4, 339

    CrossRef

  80. 80
    Yu-Bing Zhu, Qian Zhang, Jian-Jun Zou, Cui-Xia Yu, Da-Wei Xiao, Optimizing high-performance liquid chromatography method with fluorescence detection for quantification of tamoxifen and two metabolites in human plasma: Application to a clinical study, Journal of Pharmaceutical and Biomedical Analysis, 2008, 46, 2, 349

    CrossRef

  81. 81
    M. Hickey, C. Saunders, A. Partridge, N. Santoro, H. Joffe, V. Stearns, Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer, Annals of Oncology, 2008, 19, 10, 1669

    CrossRef

  82. 82
    Jea-Hwan Lee, Dong-Sun Shin, Hyun-Ah Kim, Yang-Hee Kim, Nam-Sun Paik, Nan-Mo Moon, Woo-Chul Noh, Recovery of Ovarian Function with Aromatase Inhibitors: In Young Breast Cancer Patients (<45) with Chemotherapy-induced Amenorrhea, Journal of Breast Cancer, 2008, 11, 3, 133

    CrossRef

  83. 83
    Sarah J Needleman, Jeffrey S Tobias, Review of the ATAC study: tamoxifen versus anastrozole in early-stage breast cancer, Expert Review of Anticancer Therapy, 2008, 8, 12, 1871

    CrossRef

  84. 84
    Christina I. Herold, Kimberly L. Blackwell, The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer, The Breast, 2008, 17, S15

    CrossRef

  85. 85
    Rowan T. Chlebowski, Translating trial data into patients benefits: Making the right choice, The Breast, 2008, 17, 9

    CrossRef

  86. 86
    Yang Song, George Y. H. Chi, A method for testing a prespecified subgroup in clinical trials, Statistics in Medicine, 2007, 26, 19
    Direct Link:
  87. 87
    Jean-Marc Nabholtz, Anastrozole therapy for postmenopausal women with early breast cancer, Expert Review of Obstetrics & Gynecology, 2007, 2, 3, 279

    CrossRef

  88. 88
    Serdar E. Bulun, Dong Chen, Meiling Lu, Hong Zhao, Youhong Cheng, Masashi Demura, Bertan Yilmaz, Regina Martin, Hiroki Utsunomiya, Steven Thung, Emily Su, Erica Marsh, Amy Hakim, Ping Yin, Hiroshi Ishikawa, Sanober Amin, Gonca Imir, Bilgin Gurates, Erkut Attar, Scott Reierstad, Joy Innes, Zhihong Lin, Aromatase excess in cancers of breast, endometrium and ovary, The Journal of Steroid Biochemistry and Molecular Biology, 2007, 106, 1-5, 81

    CrossRef

  89. 89
    Yukie Yonehara, Ichiro Iwamoto, Shoichiro Kosha, Yoshiaki Rai, Yoshiatsu Sagara, Tsutomu Douchi, Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients, Journal of Obstetrics and Gynaecology Research, 2007, 33, 5
    Direct Link:
  90. 90
    Sonal Gandhi, Sunil Verma, Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter, Breast Cancer Research and Treatment, 2007, 106, 1, 1

    CrossRef

  91. 91
    PierFranco Conte, Antonio Frassoldati, Aromatase Inhibitors in the Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer: Putting Safety Issues into Perspective, The Breast Journal, 2007, 13, 1
    Direct Link:
  92. 92
    R. Bell, J. Lewis, Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer, Current Medical Research and Opinion, 2007, 23, 5, 1045

    CrossRef

  93. 93
    Tessa Cigler, Paul E. Goss, Breast Cancer Adjuvant Endocrine Therapy, The Cancer Journal, 2007, 13, 3, 148

    CrossRef

  94. 94
    S. Gonnelli, A. Cadirni, C. Caffarelli, R. Petrioli, A. Montagnani, M.B. Franci, B. Lucani, G. Francini, R. Nuti, Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane, Bone, 2007, 40, 1, 205

    CrossRef

  95. 95
    Gershon Y. Locker, Robert Mansel, David Cella, Deborah Dobrez, Sonja Sorensen, Sanjay K. Gandhi, Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial, Breast Cancer Research and Treatment, 2007, 106, 2, 229

    CrossRef

  96. 96
    R Mansel, G Locker, L Fallowfield, Á Benedict, D Jones, Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen alone or in combination) trial, British Journal of Cancer, 2007, 97, 2, 152

    CrossRef

  97. 97
    C. Skedgel, D. Rayson, R. Dewar, T. Younis, Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: Upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole, The Breast, 2007, 16, 3, 252

    CrossRef

  98. 98
    Sandra Lewis, Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?, American Heart Journal, 2007, 153, 2, 182

    CrossRef

  99. 99
    Cynthia Owusu, Timothy L. Lash, Rebecca A. Silliman, Effectiveness of Adjuvant Tamoxifen Therapy among Older Women with Early Stage Breast Cancer, The Breast Journal, 2007, 13, 4
    Direct Link:
  100. 100
    Carrie Tompkins Stricker, Endocrine Effects of Breast Cancer Treatment, Seminars in Oncology Nursing, 2007, 23, 1, 55

    CrossRef

  101. 101
    Komal Jhaveri, Peter Halperin, Sandra J. Shin, Linda Vahdat, Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature, Breast Cancer Research and Treatment, 2007, 106, 3, 315

    CrossRef

  102. 102
    Christa K Baumann, Monica Castiglione-Gertsch, Estrogen Receptor Modulators and Down Regulators, Drugs, 2007, 67, 16, 2335

    CrossRef

  103. 103
    C.B. Confavreux, A. Fontana, J.P. Guastalla, F. Munoz, J. Brun, P.D. Delmas, Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates, Bone, 2007, 41, 3, 346

    CrossRef

  104. 104
    Edgardo Rivera, Evaluating adjuvant hormonal therapy in early-stage breast cancer: a comparison of predictive decision models, Community Oncology, 2007, 4, 5, 277

    CrossRef

  105. 105
    J. Ginés Rubió, F. Fernández Cortés, J. Rifá Ferrer, Inhibidores de la aromatasa en el tratamiento adyuvante de pacientes postmenopáusicas con cáncer de mama. Metanálisis, Farmacia Hospitalaria, 2007, 31, 1, 5

    CrossRef

  106. 106
    J. J. Body, P. Bergmann, S. Boonen, Y. Boutsen, J. P. Devogelaer, S. Goemaere, J. Y. Reginster, S. Rozenberg, J. M. Kaufman, Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club, Osteoporosis International, 2007, 18, 11, 1439

    CrossRef

  107. 107
    Vittal S.R. Rao, Veerabhadra Garimella, Meiju Hwang, Philip J. Drew, Management of early breast cancer in the elderly, International Journal of Cancer, 2007, 120, 6
    Direct Link:
  108. 108
    Louise J. Bordeleau, Joan E. Lipa, Peter C. Neligan, Management of the BRCA Mutation Carrier or High-Risk Patient, Clinics in Plastic Surgery, 2007, 34, 1, 15

    CrossRef

  109. 109
    Frances M. Palmieri, Edith A. Perez, Managing High-Risk Breast Cancer, Seminars in Oncology Nursing, 2007, 23, 1, 29

    CrossRef

  110. 110
    Catherine M. Bender, Susan M. Sereika, Adam M. Brufsky, Christopher M. Ryan, Victor G. Vogel, Priya Rastogi, Susan M. Cohen, Frances E. Casillo, Sarah L. Berga, Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer, Menopause, 2007, 14, 6, 995

    CrossRef

  111. 111
    Hiroyuki Takei, Kimito Suemasu, Kenichi Inoue, Tsuyoshi Saito, Katsuhiko Okubo, Junichi Koh, Kazuhiko Sato, Hitoshi Tsuda, Masafumi Kurosumi, Toshio Tabei, Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03), Breast Cancer Research and Treatment, 2007, 107, 1, 87

    CrossRef

  112. 112
    Michael Untch, Christian Jackisch, Optimal Treatment Strategies in Hormone-Responsive Early Breast Cancer: The Role of Aromatase Inhibitors, Onkologie, 2007, 30, 1-2, 55

    CrossRef

  113. 113
    José Manuel Olmos Martínez, Jesús González Macías, Osteoporosis tras la curación tumoral, Medicina Clínica, 2007, 129, 17, 669

    CrossRef

  114. 114
    Bradley J. Huth, Dennis M. Sopka, Jay Reiff, Lydia T. Komarnicky-Kocher, Partial Breast Irradiation: Is This a Viable Option?, Seminars in Breast Disease, 2007, 10, 4, 152

    CrossRef

  115. 115
    Katherine L. Kahn, Eric C. Schneider, Jennifer L. Malin, John L. Adams, Arnold M. Epstein, Patient Centered Experiences in Breast Cancer, Medical Care, 2007, 45, 5, 431

    CrossRef

  116. 116
    Vladimir F. Semiglazov, Vladislav V. Semiglazov, Garik A. Dashyan, Elena K. Ziltsova, Vadim G. Ivanov, Alla A. Bozhok, Olga A. Melnikova, Ruslan M. Paltuev, Alexander Kletzel, Lev M. Berstein, Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer, Cancer, 2007, 110, 2
    Direct Link:
  117. 117
    Katherine D. Crew, Jillian L. Capodice, Heather Greenlee, Arlyn Apollo, Judith S. Jacobson, George Raptis, Kimberly Blozie, Alex Sierra, Dawn L. Hershman, Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients, Journal of Cancer Survivorship, 2007, 1, 4, 283

    CrossRef

  118. 118
    Jean-Pierre Bergerat, Place actuelle des inhibiteurs de l'aromatase dans le traitement adjuvant des cancers du sein, La Presse Médicale, 2007, 36, 2, 333

    CrossRef

  119. 119
    Mona Sanghani, Ethan Balk, Blake Cady, David Wazer, Predicting the Risk of Local Recurrence in Patients With Breast Cancer, American Journal of Clinical Oncology, 2007, 30, 5, 473

    CrossRef

  120. 120
    K. Gelmon, Prescribing extended adjuvant letrozole, The Breast, 2007, 16, 5, 446

    CrossRef

  121. 121
    Byung Joo Song, Seon Wook Cha, Ja Seong Bae, Young Jin Seo, Woo Chan Park, Han-Seong Kim, Se Jung Oh, Jeong Soo Kim, Sang Seol Jung, Role of Zoledronic Acid on Bone Loss by Letrozole, Journal of Breast Cancer, 2007, 10, 1, 43

    CrossRef

  122. 122
    Peter Andreas Fasching, Christian R. Loehberg, Pamela L. Strissel, Michael P. Lux, Mayada R. Bani, Michael Schrauder, Sonja Geiler, Kerstin Ringleff, Sonja Oeser, Sebastian Weihbrecht, Rüdiger Schulz-Wendtland, Arndt Hartmann, Matthias W. Beckmann, Reiner Strick, Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients, Breast Cancer Research and Treatment, 2007, 112, 1, 89

    CrossRef

  123. 123
    Paul Goss, Leonie von Eichel, Summary of aromatase inhibitor trials: The past and future, The Journal of Steroid Biochemistry and Molecular Biology, 2007, 106, 1-5, 40

    CrossRef

  124. 124
    Francesco Boccardo, Alessandra Rubagotti, Daniela Aldrighetti, Franco Buzzi, Giorgio Cruciani, Antonio Farris, Giorgio Mustacchi, Mauro Porpiglia, Giorgio Schieppati, Piero Sismondi, Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma, Cancer, 2007, 109, 6
    Direct Link:
  125. 125
    Jack Cuzick, The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer, Expert Review of Anticancer Therapy, 2007, 7, 8, 1089

    CrossRef

  126. 126
    Raewyn Poole, Robert Paridaens, The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review, Current Opinion in Oncology, 2007, 19, 6, 564

    CrossRef

  127. 127
    G. Arpino, C. Gutierrez, H. Weiss, M. Rimawi, S. Massarweh, L. Bharwani, S. De Placido, C. K. Osborne, R. Schiff, Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent HER-Targeted Therapy, JNCI Journal of the National Cancer Institute, 2007, 99, 9, 694

    CrossRef

  128. 128
    Stefan Paepke, Volker R. Jacobs, Ralf Ohlinger, Mathias Warm, Sherko Kümmel, Anke Thomas, Nadia Harbeck, Marion Kiechle-Bahat, Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: AIs upfront vs. switching, Journal of Cancer Research and Clinical Oncology, 2007, 133, 12, 905

    CrossRef

  129. 129
    Jennifer L. Lycette, Shiuh-Wen Luoh, Tomasz M. Beer, Thomas G. Deloughery, Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: case report and review of the literature, Breast Cancer Research and Treatment, 2006, 99, 3, 249

    CrossRef

  130. 130
    Quyen D. Chu, John C. McDonald, Benjamin D.L. Li, Adjuvant Therapy for Patients Who Have Node-Positive Breast Cancer, Advances in Surgery, 2006, 40, 77

    CrossRef

  131. 131
    Jing Fan, Roberta McKean-Cowdin, Leslie Bernstein, Frank Z. Stanczyk, Arthur Xuejun Li, Rachel Ballard-Barbash, Anne McTiernan, Richard Baumgartner, Frank Gilliland, An association between a common variant (G972R) in the IRS-1 gene and sex hormone levels in post-menopausal breast cancer survivors, Breast Cancer Research and Treatment, 2006, 99, 3, 323

    CrossRef

  132. 132
    Aman U Buzdar, Anastrozole for breast cancer: recent advances and ongoing challenges, Expert Review of Anticancer Therapy, 2006, 6, 6, 839

    CrossRef

  133. 133
    A. Rocchi, S. Verma, Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis, Supportive Care in Cancer, 2006, 14, 9, 917

    CrossRef

  134. 134
    A. Junker, ASCO 2006, Der Onkologe, 2006, 12, 9, 934

    CrossRef

  135. 135
    Muzaffer Cicek, Merry Jo Oursler, Breast cancer bone metastasis and current small therapeutics, Cancer and Metastasis Reviews, 2006, 25, 4, 635

    CrossRef

  136. 136
    Jack Cuzick, Chemoprevention of breast cancer, Women's Health, 2006, 2, 6, 853

    CrossRef

  137. 137
    Ting Bao, Tatiana Prowell, Vered Stearns, Chemoprevention of Breast Cancer: Tamoxifen, Raloxifene, and Beyond, American Journal of Therapeutics, 2006, 13, 4, 337

    CrossRef

  138. 138
    F.J. Esteva, G.N. Hortobagyi, Comparative assessment of lipid effects of endocrine therapy for breast cancer: Implications for cardiovascular disease prevention in postmenopausal women, The Breast, 2006, 15, 3, 301

    CrossRef

  139. 139
    Tomoyoshi Suzuki, Masakazu Toi, Shigehira Saji, Kazumi Horiguchi, Tomoyuki Aruga, Eiji Suzuki, Shinichiro Horiguchi, Nobuaki Funata, Katsuyuki Karasawa, Noriko Kamata, Early breast cancer, International Journal of Clinical Oncology, 2006, 11, 2, 108

    CrossRef

  140. 140
    Cristian Massacesi, Elena Sabbatini, Marco B Rocchi, Laura Zepponi, Simonetta Rossini, Alberta Pilone, Luciano Burattini, Marco Pezzoli, Effects of Switching from Tamoxifen to Anastrozole on Tamoxifen-Related Endocrine Symptoms and Quality of Life, American Journal of Cancer, 2006, 5, 6, 433

    CrossRef

  141. 141
    Eugene McCloskey, Effects of third-generation aromatase inhibitors on bone, European Journal of Cancer, 2006, 42, 8, 1044

    CrossRef

  142. 142
    Coy Heldermon, Matthew Ellis, Endocrine therapy for breast cancer, Update on Cancer Therapeutics, 2006, 1, 3, 285

    CrossRef

  143. 143
    G Francini, R Petrioli, A Montagnani, A Cadirni, S Campagna, E Francini, S Gonnelli, Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids, British Journal of Cancer, 2006, 95, 2, 153

    CrossRef

  144. 144
    Giancarlo Garuti, Fulvia Cellani, Giovanna Centinaio, Giulia Sita, Giulio Nalli, Massimo Luerti, Histopathologic behavior of endometrial hyperplasia during tamoxifen therapy for breast cancer, Gynecologic Oncology, 2006, 101, 2, 269

    CrossRef

  145. 145
    William R. Miller, John M. S. Bartlett, Peter Canney, Mark Verrill, Hormonal therapy for postmenopausal breast cancer: the science of sequencing, Breast Cancer Research and Treatment, 2006, 103, 2, 149

    CrossRef

  146. 146
    Aman U. Buzdar, Jean-Paul Guastalla, Jean-Marc Nabholtz, Jack Cuzick, Impact of chemotherapy regimens prior to endocrine therapy, Cancer, 2006, 107, 3
    Direct Link:
  147. 147
    Henning T. Mouridsen, Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women, Current Medical Research and Opinion, 2006, 22, 8, 1609

    CrossRef

  148. 148
    X. Nogués I Solán, Inhibidores de la aromatasa y osteoporosis, Revista Española de Enfermedades Metabólicas Óseas, 2006, 15, 3, 55

    CrossRef

  149. 149
    Matthew J. Ellis, Caron E. Rigden, Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data, Current Medical Research and Opinion, 2006, 22, 12, 2479

    CrossRef

  150. 150
    Tomofumi Ohsako, Katsuhiko Inoue, Norihide Nagamoto, Yasushi Yoshida, Osamu Nakahara, Namiko Sakamoto, Joint symptoms: A practical problem of anastrozole, Breast Cancer, 2006, 13, 3, 284

    CrossRef

  151. 151
    Adam Brufsky, Management of Cancer-Treatment–Induced Bone Loss in Postmenopausal Women Undergoing Adjuvant Breast Cancer Therapy: A Z-FAST Update, Seminars in Oncology, 2006, 33, 13

    CrossRef

  152. 152
    David Buchanan, Moral reasoning as a model for health promotion, Social Science & Medicine, 2006, 63, 10, 2715

    CrossRef

  153. 153
    A. Lesur, B. Cutuli, M.-P. Teissier, E. Luporsi, Place des inhibiteurs de l’aromatase dans le cancer du sein de la femme ménopausée, en situation adjuvante: les acquis et les incertitudes en 2005, Journal de Gynécologie Obstétrique et Biologie de la Reproduction, 2006, 35, 4, 327

    CrossRef

  154. 154
    Nicholas J. Robert, Reducing the risk of recurrence in postmenopausal women with early breast cancer: a role for aromatase inhibitors, Community Oncology, 2006, 3, 5, 275

    CrossRef

  155. 155
    K. Höffken, H. G. Sayer, O. Camara, I. B. Runnebaum, F. Jänicke, Risikoadaptierte Hormontherapie des primär operablen Mammakarzinoms, Der Onkologe, 2006, 12, 7, 662

    CrossRef

  156. 156
    Jean-Marc Nabholtz, Role of Anastrozole across the Breast Cancer Continuum: From Advanced to Early Disease and Prevention, Oncology, 2006, 70, 1, 1

    CrossRef

  157. 157
    Emilio Alba, Antonio Llombart, Nuria Ribelles, Manuel Ramos, Roberto Fernández, José Ignacio Mayordomo, Ignasi Tusquets, Miguel Gil, Agustí Barnadas, Francisco Carabante, Manuel Ruiz, Ruth Vera, Isabel Palomero, Vicente Soriano, Jesús González, Ramón Colomer, Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole, Clinical and Translational Oncology, 2006, 8, 3, 193

    CrossRef

  158. 158
    Jennifer R. Garreau, Tammy DeLaMelena, Deb Walts, Kasra Karamlou, Nathalie Johnson, Side effects of aromatase inhibitors versus tamoxifen: the patients’ perspective, The American Journal of Surgery, 2006, 192, 4, 496

    CrossRef

  159. 159
    Jean-Mathieu Beauregard, Éric Turcotte, François Bénard, Steroid Receptor Imaging in Breast Cancer, PET Clinics, 2006, 1, 1, 51

    CrossRef

  160. 160
    Paul E. Goss, Shangle Qi, Haiqing Hu, Angela M. Cheung, The effects of atamestane and toremifene alone and in combination compared with letrozole on bone, serum lipids and the uterus in an ovariectomized rat model, Breast Cancer Research and Treatment, 2006, 103, 3, 293

    CrossRef

  161. 161
    A. Monnier, The evolving role of letrozole in the adjuvant setting: First results from the large, phase III, randomized trial BIG 1-98, The Breast, 2006, 15, 1, 21

    CrossRef

  162. 162
    Rinaa S. Punglia, Karen M. Kuntz, Eric P. Winer, Jane C. Weeks, Harold J. Burstein, The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer, Cancer, 2006, 106, 12
    Direct Link:
  163. 163
    John F. Forbes, The Use of Early Adjuvant Aromatase Inhibitor Therapy: Contributions From the BIG 1-98 Letrozole Trial, Seminars in Oncology, 2006, 33, 2

    CrossRef

  164. 164
    Robert W Brueggemeier, Update on the use of aromatase inhibitors in breast cancer, Expert Opinion on Pharmacotherapy, 2006, 7, 14, 1919

    CrossRef

  165. 165
    A.U. Buzdar, 1–42 A Randomized Trial of Exemestane After Two to Three Years of Tamoxifen Therapy in Postmenopausal Women With Primary Breast Cancer, Breast Diseases: A Year Book Quarterly, 2005, 16, 1, 80

    CrossRef

  166. 166
    A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer, New England Journal of Medicine, 2005, 353, 26, 2747

    CrossRef

  167. 167
    M. C. Gainford, C. Simmons, H. Nguyen, S. Verma, M. Clemons, A practical guide to the management of menopausal symptoms in breast cancer patients, Supportive Care in Cancer, 2005, 13, 8, 573

    CrossRef

  168. 168
    Gabriele Martelli, Patrizia Boracchi, Michaela De Palo, Silvana Pilotti, Saro Oriana, Roberto Zucali, Maria Grazia Daidone, Giuseppe De Palo, A Randomized Trial Comparing Axillary Dissection to No Axillary Dissection in Older Patients With T1N0 Breast Cancer, Annals of Surgery, 2005, 242, 1, 1

    CrossRef

  169. 169
    Nan Soon Wong, Kathleen I Pritchard, A review of exemestane in the management of breast cancer, Expert Opinion on Pharmacotherapy, 2005, 6, 13, 2353

    CrossRef

  170. 170
    Hans Wildiers, Etienne G.C Brain, Adjuvant chemotherapy in elderly patients with breast cancer: where are we?, Current Opinion in Oncology, 2005, 17, 6, 566

    CrossRef

  171. 171
    Silvia Dellapasqua, Monica Castiglione-Gertsch, Adjuvant endocrine therapies for postmenopausal women with early breast cancer: Standards and not, The Breast, 2005, 14, 6, 555

    CrossRef

  172. 172
    Kathrin Strasser-Weippl, Paul E. Goss, Adjuvant endocrine therapy options in hormone-dependent breast cancer, European Journal of Cancer Supplements, 2005, 3, 3, 247

    CrossRef

  173. 173
    Walter Jonat, Felix Hilpert, Advanced disease — the optimal sequential treatment strategy, European Journal of Cancer Supplements, 2005, 3, 3, 237

    CrossRef

  174. 174
    Susan Peck, Joyce A. O'Shaughnessy, Sara Mariani, Advances in the Use of Aromatase Inhibitors: Updates from San Antonio and St. Gallen, Clinical Breast Cancer, 2005, 6, 1, 23

    CrossRef

  175. 175
    Anthony Howell, Anastrozole: a new gold standard of hormonal treatment for breast cancer?, Women's Health, 2005, 1, 3, 309

    CrossRef

  176. 176
    C. Lattrich, I. Juhasz-Böss, F. Horn, O. Ortmann, Antitumorale Wirkungen und Nebenwirkungen von Aromatasehemmern, Gynäkologische Endokrinologie, 2005, 3, 4, 271

    CrossRef

  177. 177
    Anthony Howell, Aman Buzdar, Are aromatase inhibitors superior to antiestrogens?, The Journal of Steroid Biochemistry and Molecular Biology, 2005, 93, 2-5, 237

    CrossRef

  178. 178
    Theodoros Agorastos, Violeta Vaitsi, Konstantinos Pantazis, Efstathios Efstathiadis, Dimitrios Vavilis, John N. Bontis, Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women, European Journal of Obstetrics & Gynecology and Reproductive Biology, 2005, 118, 2, 239

    CrossRef

  179. 179
    N. S. Wong, K. I. Pritchard, Aromatase inhibitors as adjuvant therapy: how will results of the ATAC trial at San Antonio 2004 and BIG 1-98 at St Gallen 2005 impact on aromatase inhibitors as adjuvant endocrine therapy?, Breast Cancer Online, 2005, 8, 12

    CrossRef

  180. 180
    A S Bhatnagar, Aromatase inhibitors in advanced breast cancer: there are efficacy differences, British Journal of Cancer, 2005, 92, 6, 1173

    CrossRef

  181. 181
    Cynthia Osborne, Debu Tripathy, Aromatase Inhibitors: Rationale and Use in Breast Cancer, Annual Review of Medicine, 2005, 56, 1, 103

    CrossRef

  182. 182
    Per E. Lønning, Jürgen Geisler, Aromatase inhibitors—Socio-economical issues, The Journal of Steroid Biochemistry and Molecular Biology, 2005, 95, 1-5, 137

    CrossRef

  183. 183
    J Lester, R Coleman, Bone loss and the aromatase inhibitors, British Journal of Cancer, 2005, 93, S16

    CrossRef

  184. 184
    C.A. Rodríguez Sánchez, Cáncer de mama (y II). Estrategias terapéuticas, Medicine - Programa de Formación Médica Continuada Acreditado, 2005, 9, 26, 1692

    CrossRef

  185. 185
    Richard C. Cabot, Nancy Lee Harris, Jo-Anne O. Shepard, Sally H. Ebeling, Stacey M. Ellender, Christine C. Peters, Paula D. Ryan, Daniel B. Kopans, Dennis C. Sgroi, Case 24-2005, New England Journal of Medicine, 2005, 353, 6, 617

    CrossRef

  186. 186
    Case 24-2005: A Woman with Estrogen-Receptor–Positive Breast Cancer, New England Journal of Medicine, 2005, 353, 21, 2304

    CrossRef

  187. 187
    Catherine Van Poznak, Nicholas P. Sauter, Clinical management of osteoporosis in women with a history of breast carcinoma, Cancer, 2005, 104, 3
    Direct Link:
  188. 188
    Filippo Montemurro, Stefania Redana, Giorgio Valabrega, Massimo Aglietta, Controversies in breast cancer: adjuvant and neoadjuvant therapy, Expert Opinion on Pharmacotherapy, 2005, 6, 7, 1055

    CrossRef

  189. 189
    Susana M. Campos, Evolving treatment approaches for early breast cancer, Breast Cancer Research and Treatment, 2005, 89, S1, S1

    CrossRef

  190. 190
    Simon Chowdhury, Paul Ellis, Extended adjuvant endocrine therapy of early breast cancer, Current Medical Research and Opinion, 2005, 21, 12, 1985

    CrossRef

  191. 191
    William Gradishar, Fulvestrant in the treatment of postmenopausal women with advanced breast cancer, Expert Review of Anticancer Therapy, 2005, 5, 3, 445

    CrossRef

  192. 192
    Anthony Howell, John Pippen, Richard M. Elledge, Louis Mauriac, Ignace Vergote, Stephen E. Jones, Steven E. Come, C. Kent Osborne, John F.R. Robertson, Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma, Cancer, 2005, 104, 2
    Direct Link:
  193. 193
    Lisa E. Sokolowicz, William J. Gradishar, Hormonal therapy for primary breast cancer: Scientific rationale and status of clinical research, Current Oncology Reports, 2005, 7, 1, 31

    CrossRef

  194. 194
    Greger Nilsson, Lars Holmberg, Hans Garmo, Andreas Terent, Carl Blomqvist, Increased incidence of stroke in women with breast cancer, European Journal of Cancer, 2005, 41, 3, 423

    CrossRef

  195. 195
    Jack Cuzick, Letter to the editor, Statistics in Medicine, 2005, 24, 10
    Direct Link:
  196. 196
    Manfred Kaufmann, Achim Rody, Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy, Journal of Cancer Research and Clinical Oncology, 2005, 131, 8, 487

    CrossRef

  197. 197
    C. Thomssen, Mammakarzinom?Standards der Versorgung heute und morgen, Der Onkologe, 2005, 11, 3, 265

    CrossRef

  198. 198
    N J Bundred, N L P Barnes, Potential use of COX-2–aromatase inhibitor combinations in breast cancer, British Journal of Cancer, 2005, 93, S10

    CrossRef

  199. 199
    Diana Lüftner, Petra Henschke, Diane Pollmann, Steffi Schildhauer, Kurt Possinger, Prescription Pattern of Aromatase Inhibitors in the Adjuvant Setting in Germany – Final Results of a Survey Among German Breast Cancer Specialists, Onkologie, 2005, 28, 12, 000

    CrossRef

  200. 200
    R Sainsbury, Reply: aromatase inhibition in advanced breast cancer: no conclusive evidence of efficacy differences, British Journal of Cancer, 2005, 92, 6, 1175

    CrossRef

  201. 201
    Powel Brown, Risk Assessment: Controversies and Management of Moderate- to High-Risk Individuals, The Breast Journal, 2005, 11,
    Direct Link:
  202. 202
    William J. Gradishar, Safety Considerations of Adjuvant Therapy in Early Breast Cancer in Postmenopausal Women, Oncology, 2005, 69, 1, 1

    CrossRef

  203. 203
    Riccardo Ponzone, Piero Sismondi, Selected highlights from the 27th San Antonio Breast Cancer Symposium, Expert Opinion on Pharmacotherapy, 2005, 6, 7, 1257

    CrossRef

  204. 204
    John R. Mackey, Anil A. Joy, Skeletal health in postmenopausal survivors of early breast cancer, International Journal of Cancer, 2005, 114, 6
    Direct Link:
  205. 205
    Jeremy B. Wiygul, Brian R. Evans, Bercedis L. Peterson, Thomas J. Polascik, Philip J. Walther, Cary N. Robertson, David M. Albala, Wendy Demark-Wahnefried, Supplement use among men with prostate cancer, Urology, 2005, 66, 1, 161

    CrossRef

  206. 206
    D.G.R. Evans, F. Lalloo, P. Hopwood, A. Maurice, A. Baildam, A. Brain, L. Barr, A. Howell, Surgical decisions made by 158 women with hereditary breast cancer aged <50 years, European Journal of Surgical Oncology (EJSO), 2005, 31, 10, 1112

    CrossRef

  207. 207
    J. Kirkby-Bott, G. Cunnick, M.W. Kissin, T1 G1 NO ER positive breast cancer—adjuvant therapy is needed, European Journal of Surgical Oncology (EJSO), 2005, 31, 4, 369

    CrossRef

  208. 208
    Debu Tripathy, Targeted Therapies in Breast Cancer, The Breast Journal, 2005, 11,
    Direct Link:
  209. 209
    Jennifer B. Manders, William J. Gradishar, The evolving role of endocrine therapy for early stage breast cancer, Breast Cancer, 2005, 12, 2, 62

    CrossRef

  210. 210
    Alberto J. Montero, Roman Rouzier, Ana Lluch, Richard L. Theriault, Aman U. Buzdar, Suzette Delaloge, Begoñia Bermejo, Monique Le, Shu-Wan Kau, Ariane Dunant, Rodrigo Arriagada, Marc Spielmann, Javier Garcia-Conde, Aysegul A. Sahin, Sonja E. Singletary, Gabriel N. Hortobagyi, Vicente Valero, The natural history of breast carcinoma in patients with ≥ 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy, Cancer, 2005, 104, 2
    Direct Link:
  211. 211
    A. U. Buzdar, The role of aromatase inhibitors as adjuvant therapy in early breast cancer, Breast Cancer Online, 2005, 7, 10

    CrossRef

  212. 212
    Walter Jonat, Felix Hilpert, Nicolai Maass, The use of aromatase inhibitors in adjuvant therapy for early breast cancer, Cancer Chemotherapy and Pharmacology, 2005, 56, S1, 32

    CrossRef

  213. 213
    R. Jones, R. C. F. Leonard, Treating elderly patients with breast cancer, Breast Cancer Online, 2005, 8, 04

    CrossRef

  214. 214
    Kerin B Adelson, Charles L Loprinzi, Dawn L Hershman, Treatment of hot flushes in breast and prostate cancer, Expert Opinion on Pharmacotherapy, 2005, 6, 7, 1095

    CrossRef

  215. 215
    Anthony Howell, Jack Cuzick, Vascular effects of aromatase inhibitors: Data from clinical trials, The Journal of Steroid Biochemistry and Molecular Biology, 2005, 95, 1-5, 143

    CrossRef

  216. 216
    M. Toi, H. Bando, H.A. Weich, Vascular endothelial growth factor and its relationships with endogenous inhibitors in a breast cancer microenvironment manipulated by hormonal therapy: a hypothetical consideration, Biomedicine & Pharmacotherapy, 2005, 59, S344

    CrossRef

  217. 217
    Rebecca B. Riggins, Amy H. Bouton, Minetta C. Liu, Robert Clarke, Vitamins & Hormones Volume 71, 2005,

    CrossRef

  218. 218
    M.N.G. Dukes, Side Effects of Drugs Annual Volume 28, 2005,

    CrossRef

  219. 219
    Lori Johnson, Jennifer Klem, David Lee, Kavita Maung, Vinay K. Jain, Joyce A. O'Shaughnessy, 2003 Highlights From: 26th Annual San Antonio Breast Cancer Symposium; San Antonio, Texas, December 3-6, 2003, Clinical Breast Cancer, 2004, 4, 6, 382

    CrossRef

  220. 220
    Margaret Grant, Daniel W Rea, Adjuvant endocrine therapy for postmenopausal women with early stage breast cancer, Therapy, 2004, 1, 2, 305

    CrossRef

  221. 221
    Margaret Grant, Daniel W Rea, Adjuvant endocrine therapy for postmenopausal women with early stage breast cancer, Therapy, 2004, 1, 2, 305

    CrossRef

  222. 222
    Betty A. Mincey, Edith A. Perez, Advances in Screening, Diagnosis, and Treatment of Breast Cancer, Mayo Clinic Proceedings, 2004, 79, 6, 810

    CrossRef

  223. 223
    Betty A. Mincey, Edith A. Perez, Advances in Screening, Diagnosis, and Treatment of Breast Cancer, Mayo Clinic Proceedings, 2004, 79, 6, 810

    CrossRef

  224. 224
    Fritz Jänicke, Are all aromatase inhibitors the same? A review of the current evidence, The Breast, 2004, 13, 1, 10

    CrossRef

  225. 225
    Peter M. Ravdin, Aromatase inhibitors in adjuvant therapy: promise and uncertainty, Community Oncology, 2004, 1, 4, 219

    CrossRef

  226. 226
    Ian E. Smith, Aromatase inhibitors in early breast cancer therapy, Seminars in Oncology, 2004, 31, 9

    CrossRef

  227. 227
    I.Craig Henderson, Aromatase inhibitors in the management of early breast cancer: Optimizing the clinical benefit, Seminars in Oncology, 2004, 31, 31

    CrossRef

  228. 228
    Ian E. Smith, Aromatase inhibitors—extending the benefits of adjuvant therapy beyond tamoxifen, The Breast, 2004, 13, 1, 3

    CrossRef

  229. 229
    Bruce E. Hillner, Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor–positive breast cancer, Cancer, 2004, 101, 6
    Direct Link:
  230. 230
    Mitch Dowsett, Biomarker investigations from the ATAC trial: the role of TA01, Breast Cancer Research and Treatment, 2004, 87, 1, 11

    CrossRef

  231. 231
    Gershon Y. Locker, J. Richard Sainsbury, Jack Cuzick, Breast surgery in the ‘Arimidex, Tamoxifen Alone or in Combination’ (ATAC) trial, Cancer, 2004, 101, 4
    Direct Link:
  232. 232
    Lisa Hutchinson, Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer?, Nature Clinical Practice Oncology, 2004, 1, 1, 24

    CrossRef

  233. 233
    K. Tada, M. Yoshimoto, S. Nishimura, K. Takahashi, M. Makita, T. Iwase, S. Takahashi, Y. Ito, K. Hatake, M. Ueno, K. Nakagawa, F. Kasumi, Comparison of two-year and five-year tamoxifen use in Japanese post-menopausal women, European Journal of Surgical Oncology (EJSO), 2004, 30, 10, 1077

    CrossRef

  234. 234
    V. Stearns, N. E. Davidson, Deja Vu for Breast Cancer Two?, JNCI Journal of the National Cancer Institute, 2004, 96, 7, 497

    CrossRef

  235. 235
    S. Packianathan, Rajendra G. Mehta, Rajeshwari R. Mehta, William H. Hall, Philip S. Boerner, Laurel A. Beckett, Srinivasan Vijayakumar, Designing a Randomized Phase I/II Prostate Cancer Chemoprevention Trial Using 1??-Hydroxy-24-Ethyl-Cholecalciferol, an Analogue of Vitamin D3, The Cancer Journal, 2004, 10, 6, 357

    CrossRef

  236. 236
    Mitch Dowsett, Designing the future shape of breast cancer diagnosis, prognosis and treatment, Breast Cancer Research and Treatment, 2004, 87, 1, 27

    CrossRef

  237. 237
    Mitch Dowsett, E5. Molecular basis of endocrine therapy, European Journal of Cancer Supplements, 2004, 2, 3, 12

    CrossRef

  238. 238
    Syed A Hussain, Sarah Williams, Andrea Stevens, Daniel W Rea, Endocrine therapy for early breast cancer, Expert Review of Anticancer Therapy, 2004, 4, 5, 877

    CrossRef

  239. 239
    P. Neven, I. Vergote, F. De Prins, C. De Rop, W. Tjalma, P. Van Dam, J. Van Ginderachter, Endocrine treatment and prevention of breast and gynaecological cancers, European Journal of Cancer Supplements, 2004, 2, 9, 1

    CrossRef

  240. 240
    José Baselga, Luca Gianni, Charles Geyer, Edith A. Perez, Alessandro Riva, Christian Jackisch, Future options with trastuzumab for primary systemic and adjuvant therapy, Seminars in Oncology, 2004, 31, 51

    CrossRef

  241. 241
    D Azria, C Lemanski, A Zouhair, M Gutowski, Y Belkacémi, J.B Dubois, G Romieu, M Ozsahin, Hormonoradiothérapie adjuvante concomitante des cancers du sein : état de l'art, Cancer/Radiothérapie, 2004, 8, 3, 188

    CrossRef

  242. 242
    Matti S. Aapro, Long-term implications of bone loss in breast cancer, The Breast, 2004, 13, 1, 29

    CrossRef

  243. 243
    Filippo Montemurro, Massimo Aglietta, Selected Highlights from the 26th San Antonio Breast Cancer Symposium, Expert Opinion on Pharmacotherapy, 2004, 5, 4, 981

    CrossRef

  244. 244
    Rita Kramer, Powel Brown, Should Tamoxifen Be Used in Breast Cancer Prevention?, Drug Safety, 2004, 27, 13, 979

    CrossRef

  245. 245
    Wendy Y. Chen, JoAnn E. Manson, The Letrozole Breast Cancer Trial: clinical implications and remaining questions, Women's Health Issues, 2004, 14, 1, 7

    CrossRef

  246. 246
    Paolo Morandi, Roman Rouzier, Kadri Altundag, Aman U. Buzdar, Richard L. Theriault, Gabriel Hortobagyi, The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma, Cancer, 2004, 101, 7
    Direct Link:
  247. 247
    J. Michael Dixon, The scientific value of preoperative studies and how they can be used, Breast Cancer Research and Treatment, 2004, 87, 1, 19

    CrossRef

  248. 248
    Mitch Dowsett, Translational research and the changing face of breast cancer, Breast Cancer Research and Treatment, 2004, 87, 1, 1

    CrossRef

  249. 249
    Umberto Basso, Antonella Brunello, Claudia Pogliani, Silvio Monfardini, Treatment options for early breast cancer in elderly women, Expert Review of Anticancer Therapy, 2004, 4, 2, 197

    CrossRef

  250. 250
    Preeta Tyagi, Vinay K. Jain, Joyce A. O'Shaughnessy, Use of Aromatase Inhibitors in the Adjuvant Setting: The “Switching” Trials, Clinical Breast Cancer, 2004, 5, 1, 31

    CrossRef

View Full Article (HTML) Get PDF (120K)